

CLH report

Proposal for Harmonised Classification and Labelling

Based on Regulation (EC) No 1272/2008 (CLP Regulation),
Annex VI, Part 2

Substance Name: CHLOROPHACINONE

EC Number: 223-003-0

CAS Number: 3691-35-8

Index Number: 606-014-00-9

Contact details for dossier submitter:

Version number:

Date: November 2012

CONTENTS

Part A.

1	PROPOSAL FOR HARMONISED CLASSIFICATION AND LABELLING	6
1.1	SUBSTANCE	6
1.2	HARMONISED CLASSIFICATION AND LABELLING PROPOSAL	6
2	BACKGROUND TO THE CLH PROPOSAL	14
2.1	HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING	14
2.2	SHORT SUMMARY OF THE SCIENTIFIC JUSTIFICATION FOR THE CLH PROPOSAL	14
2.3	CURRENT HARMONISED CLASSIFICATION AND LABELLING	15
2.3.1	<i>Current classification and labelling in Annex VI, Table 3.1 in the CLP Regulation</i>	<i>16</i>
2.3.2	<i>Current classification and labelling in Annex VI, Table 3.2 in the CLP Regulation</i>	<i>16</i>
2.4	CURRENT SELF-CLASSIFICATION AND LABELLING	16
2.4.1	<i>Current self-classification and labelling based on the CLP Regulation criteria</i>	<i>16</i>
2.4.2	<i>Current self-classification and labelling based on DSD criteria</i>	<i>17</i>
3	JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL	17
	SCIENTIFIC EVALUATION OF THE DATA	18
1	IDENTITY OF THE SUBSTANCE	18
1.1	NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE	18
1.2	COMPOSITION OF THE SUBSTANCE	19
1.2.1	<i>Composition of test material</i>	<i>19</i>
2	MANUFACTURE AND USES	24
2.1	MANUFACTURE	24
2.2	IDENTIFIED USES	24
3	CLASSIFICATION FOR PHYSICO-CHEMICAL PROPERTIES	25
3.1	<i>[INSERT HAZARD CLASS WHEN RELEVANT AND REPEAT SECTION IF NEEDED]</i>	<i>27</i>
3.1.1	<i>Summary and discussion of</i>	<i>27</i>
3.1.2	<i>Comparison with criteria</i>	<i>27</i>
3.1.3	<i>Conclusions on classification and labelling</i>	<i>27</i>
4	HUMAN HEALTH HAZARD ASSESSMENT	27
4.1	TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)	27
4.1.1	<i>Non-human information</i>	<i>28</i>
4.1.2	<i>Human information</i>	<i>29</i>
4.1.3	<i>Summary and discussion on toxicokinetics</i>	<i>30</i>
4.2	ACUTE TOXICITY	31
4.2.1	<i>Non-human information</i>	<i>31</i>
4.2.1.1	<i>Acute toxicity: oral</i>	<i>31</i>
4.2.1.2	<i>Acute toxicity: inhalation</i>	<i>32</i>
4.2.1.3	<i>Acute toxicity: dermal</i>	<i>32</i>
4.2.1.4	<i>Acute toxicity: other routes</i>	<i>33</i>
4.2.2	<i>Human information</i>	<i>33</i>
4.2.3	<i>Summary and discussion of acute toxicity</i>	<i>33</i>
4.2.4	<i>Comparison with criteria</i>	<i>33</i>
4.2.5	<i>Conclusions on classification and labelling</i>	<i>34</i>
4.3	SPECIFIC TARGET ORGAN TOXICITY – SINGLE EXPOSURE (STOT SE)	35
4.3.1	<i>Summary and discussion of Specific target organ toxicity – single exposure</i>	<i>35</i>
4.3.2	<i>Comparison with criteria</i>	<i>35</i>

4.3.3	<i>Conclusions on classification and labelling</i>	35
4.4	IRRITATION.....	35
4.4.1	<i>Skin irritation</i>	35
4.4.1.1	Non-human information	35
4.4.1.2	Human information.....	35
4.4.1.3	Summary and discussion of skin irritation.....	35
4.4.1.4	Comparison with criteria	35
4.4.1.5	Conclusions on classification and labelling	35
4.4.2	<i>Eye irritation</i>	36
4.4.2.1	Non-human information	36
4.4.2.2	Human information.....	36
4.4.2.3	Summary and discussion of eye irritation.....	36
4.4.2.4	Comparison with criteria	36
4.4.2.5	Conclusions on classification and labelling	36
4.4.3	<i>Respiratory tract irritation</i>	36
4.4.3.1	Non-human information	37
4.4.3.2	Human information.....	37
4.4.3.3	Summary and discussion of respiratory tract irritation	37
4.4.3.4	Comparison with criteria	37
4.4.3.5	Conclusions on classification and labelling	37
4.5	CORROSIVITY	37
4.5.1	<i>Non-human information</i>	37
4.5.2	<i>Human information</i>	37
4.5.3	<i>Summary and discussion of corrosivity</i>	37
4.5.4	<i>Comparison with criteria</i>	37
4.5.5	<i>Conclusions on classification and labelling</i>	37
4.6	SENSITISATION	37
4.6.1	<i>Skin sensitisation</i>	37
4.6.1.1	Non-human information	38
4.6.1.2	Human information.....	38
4.6.1.3	Summary and discussion of skin sensitisation	38
4.6.1.4	Comparison with criteria	38
4.6.1.5	Conclusions on classification and labelling	38
4.6.2	<i>Respiratory sensitisation</i>	38
4.6.2.1	Non-human information	38
4.6.2.2	Human information.....	38
4.6.2.3	Summary and discussion of respiratory sensitisation	38
4.6.2.4	Comparison with criteria	38
4.6.2.5	Conclusions on classification and labelling	38
4.7	REPEATED DOSE TOXICITY	39
4.7.1	<i>Non-human information</i>	40
4.7.1.1	Repeated dose toxicity: oral.....	40
4.7.1.2	Repeated dose toxicity: inhalation	42
4.7.1.3	Repeated dose toxicity: dermal.....	42
4.7.1.4	Repeated dose toxicity: other routes	43
4.7.1.5	Human information.....	43
4.7.1.6	Other relevant information.....	43
4.7.1.7	Summary and discussion of repeated dose toxicity	43
4.7.1.8	Summary and discussion of repeated dose toxicity findings relevant for classification according to DSD.....	44
4.7.1.9	Comparison with criteria of repeated dose toxicity findings relevant for classification according to DSD.....	44
4.7.1.10	Conclusions on classification and labelling of repeated dose toxicity findings relevant for classification according to DSD	44
4.8	SPECIFIC TARGET ORGAN TOXICITY (CLP REGULATION) – REPEATED EXPOSURE (STOT RE).....	44
4.8.1	<i>Summary and discussion of repeated dose toxicity findings relevant for classification as STOT RE according to CLP Regulation</i>	44
4.8.2	<i>Comparison with criteria of repeated dose toxicity findings relevant for classification as STOT RE</i>	44
4.8.3	<i>Conclusions on classification and labelling of repeated dose toxicity findings relevant for classification as STOT RE</i>	45
4.9	GERM CELL MUTAGENICITY (MUTAGENICITY)	45
4.9.1	<i>Non-human information</i>	47
4.9.1.1	In vitro data.....	47
4.9.1.2	In vivo data.....	47
4.9.2	<i>Human information</i>	47
4.9.3	<i>Other relevant information</i>	47

4.9.4	Summary and discussion of mutagenicity	48
4.9.5	Comparison with criteria	48
4.9.6	Conclusions on classification and labelling	48
4.10	CARCINOGENICITY	49
4.10.1	Non-human information	49
CARCINOGENICITY AND LONG-TERM TOXICITY STUDIES HAVE NOT BEEN PERFORMED. 49		
4.10.1.1	Carcinogenicity: oral	49
4.10.1.2	Carcinogenicity: inhalation	49
4.10.1.3	Carcinogenicity: dermal	49
4.10.2	Human information	49
4.10.3	Other relevant information	49
4.10.4	Summary and discussion of carcinogenicity	49
4.10.5	Comparison with criteria	49
4.10.6	Conclusions on classification and labelling	49
4.11	TOXICITY FOR REPRODUCTION	50
4.11.1	Effects on fertility	51
4.11.1.1	Non-human information	51
4.11.1.2	Human information	51
4.11.2	Developmental toxicity	51
4.11.2.1	Non-human information	53
4.11.2.2	Human information	53
4.11.3	Other relevant information	53
4.11.4	Summary and discussion of reproductive toxicity	53
4.11.5	Comparison with criteria	55
4.11.6	Conclusions on classification and labelling	55
4.12	OTHER EFFECTS	55
4.12.1	Non-human information	55
4.12.1.1	Neurotoxicity	55
4.12.1.2	Immunotoxicity	55
4.12.1.3	Specific investigations: other studies	55
4.12.1.4	Human information	55
4.12.2	Summary and discussion	56
4.12.3	Comparison with criteria	56
4.12.4	Conclusions on classification and labelling	56
5	ENVIRONMENTAL HAZARD ASSESSMENT	56
5.1	DEGRADATION	56
5.1.1	Stability	57
5.1.2	Biodegradation	61
5.1.2.1	Biodegradation estimation	61
5.1.2.2	Screening tests	61
5.1.2.3	Simulation tests	61
5.1.3	Summary and discussion of degradation	61
5.2	ENVIRONMENTAL DISTRIBUTION	61
	Biotic degradation in soil	61
5.2.1	Adsorption/Desorption	63
	Adsorption/desorption screening test	63
5.2.2	Volatilisation	64
5.2.3	Distribution modelling	64
5.3	AQUATIC BIOACCUMULATION	64
5.3.1	Aquatic bioaccumulation	65
5.3.1.1	Bioaccumulation estimation	65
5.3.1.2	Measured bioaccumulation data	66
5.3.2	Summary and discussion of aquatic bioaccumulation	66
5.4	AQUATIC TOXICITY	66
5.4.1	Fish	67
5.4.1.1	Short-term toxicity to fish	67
5.4.1.2	Long-term toxicity to fish	68
5.4.2	Aquatic invertebrates	68
5.4.2.1	Short-term toxicity to aquatic invertebrates	68
5.4.2.2	Long-term toxicity to aquatic invertebrates	68
5.4.3	Algae and aquatic plants	68

5.4.4 *Other aquatic organisms (including sediment)*..... 69
5.5 COMPARISON WITH CRITERIA FOR ENVIRONMENTAL HAZARDS (SECTIONS 5.1 – 5.4) 69
5.6 CONCLUSIONS ON CLASSIFICATION AND LABELLING FOR ENVIRONMENTAL HAZARDS (SECTIONS 5.1 – 5.4) .. 70
6 OTHER INFORMATION..... 71
7 REFERENCES..... 73

Part A.

1 PROPOSAL FOR HARMONISED CLASSIFICATION AND LABELLING

1.1 Substance

Table 1: Substance identity

Substance name:	<i>CHLOROPHACINONE</i>
EC number:	223-003-0
CAS number:	3691-35-8
Annex VI Index number:	606-014-00-9
Degree of purity:	> 97.8%
Impurities:	Information on the impurities is considered confidential and it is presented in the confidential attachment to the draft CA-report on Chlorophacinone.

1.2 Harmonised classification and labelling proposal

Table 2: The current Annex VI entry and the proposed harmonised classification

	CLP Regulation		Directive 67/548/EEC (Dangerous Substances Directive; DSD)
Current entry in Annex VI, CLP Regulation	Acute Tox. 1 Acute Tox. 2 (* Acute Tox. 3 (* STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H310 H300 H331 H372(**) H400 H410	T+; R27/28 T; R23 T; R48/24/25 N; R50-53
Current proposal for consideration by RAC (**)	Acute Tox. 1 Acute Tox. 1 Acute Tox. 2 STOT RE. 1	H330 H310 H300 H372	Hazard symbol: T+, N R phrases: <ul style="list-style-type: none"> ▪ T+; R26/27/28 ▪ T; R48/23//24/25

	According to Regulation (EC) No 1272/2008 and Regulation (EU) No 286/2011: Aquatic Acute 1 Aquatic Chronic 1	H400 H410 Acute M-factor 1 Chronic M-factor 1	<ul style="list-style-type: none"> ▪ Cn ≥ 25% N; R50-53
Resulting harmonised classification (future entry in Annex VI, CLP Regulation)	Aquatic Acute 1 Aquatic Chronic 1 Acute M-factor 1 Chronic M-factor 1	H400 H410	Cn ≥ 25% N; R50-53


(**) We sent on 23 March 2009 our Annex XV Intention. The proposal about classification included the risk phrase R61. However, the new OECD 414 study available for warfarin sodium affects the reasons for classification of chlorophacinone. This study addresses a regulatory request to investigate whether all AVK's should be classified as R61, based on read-across from warfarin sodium data.

The study carried out with warfarin sodium shows a definitive increase in incidence of subcutaneous and internal foetal haemorrhage (not seen in studies with chlorophacinone), foetal ocular effects and some indications of reduced ossification in skull bone at higher dose levels (see point 6). Similar studies have been carried out with chlorophacinone which was not embryotoxic or teratogenic in rat and rabbit.

The adverse finding detected in a standard OECD 414 study for warfarin sodium, would validate the negative findings in a similar study with chlorophacinone. Therefore, the phrase R61 is not warranted.

Proposed harmonised classification and labelling based on CLP Regulation and/or DSD criteria

1) Based on CLP Regulation:

CLASSIFICATION		LABELLING	
<u>Hazard Class and Category Code</u>	<u>Statement codes</u>	<u>Pictogram, Signal Word Code(s)</u>	<u>Hazard statement Code(s)</u>
Inhalat: Acute Tox. 1	H330 H310	GHS06, Danger	H330
Dermal: Acute Tox. 1	H300 H372	GHS06, Danger	H310
Oral: Acute Tox. 2	H400	GHS06, Danger	H300
STOT RE 1	H410	Dgr	H372
Aquatic Acute 1			H410
Aquatic Chronic 1			

Specific concentration limits:

$C \geq 0.1\%$: STOT RE 1; H372

$0.01\% \leq C < 0.1\%$: STOT RE 2; H373

2) Based on DSD criteria:

Classification : T⁺; R26/27/28, T; R48/23/24/25, N; R50-53

Labelling:

Symbol(s): T⁺, N

R-phrases: R 26/27/28- R48/23/24/25- R50/53

S-phrases: (1/2)-36/37-45-60-61

Specific concentration limits:

$C \geq 0.7\%$: T⁺; R26/27/28- 48/23/24/25

$0.1\% \leq C < 0.7\%$: T⁺; R26/27-25-48/23/24/25

$0.07\% \leq C < 0.1\%$: T⁺; R26/27-22-48/20/21/22

$0.01\% \leq C < 0.07\%$: T; R23/24-22-48/20/21/22

$0.001\% \leq C < 0.01\%$: Xn; R20/21

Table 3: Proposed classification according to the CLP Regulation

CLP Annex I ref	Hazard class	Proposed classification	Proposed SCLs and/or M-factors	Current classification ¹⁾	Reason for no classification ²⁾
2.1.	Explosives	-		None	There are no hazards associated with normal use of the active substance.
2.2.	Flammable gases	-		None	Idem
2.3.	Flammable aerosols	-		None	Idem
2.4.	Oxidising gases	-		None	Idem
2.5.	Gases under pressure	-		None	Idem
2.6.	Flammable liquids	-		None	Idem
2.7.	Flammable solids	-		None	Idem
2.8.	Self-reactive substances and mixtures	-			
2.9.	Pyrophoric liquids	-			
2.10.	Pyrophoric solids	-			
2.11.	Self-heating substances and mixtures	-			
2.12.	Substances and mixtures which in contact with water emit flammable gases	-			
2.13.	Oxidising liquids	-			
2.14.	Oxidising solids	-		None	Idem
2.15.	Organic peroxides	-		None	Idem
2.16.	Substance and mixtures corrosive to metals	-		None	Idem
3.1.	Acute toxicity - oral	Acute Tox. 2 – H300		Acute Tox. 2 – H300	
	Acute toxicity - dermal	Acute Tox. 1– H310		Acute Tox. 1– H310	
	Acute toxicity - inhalation	Acute Tox. 1– H330		Acute Tox. 3– H331	
3.2.	Skin corrosion / irritation	None		None	Chlorophacinone does not fulfil the EU criteria for classification as a skin irritant.
3.3.	Serious eye damage / eye irritation	None		None	Idem
3.4.	Respiratory sensitisation	None		None	No study available. In the acute inhalation study, it was stated there was no evidence of respiratory tract irritation following a 4 h nose only exposure.
3.4.	Skin sensitisation	None		None	In a Buehler Test, no signs of irritation were observed at any of the challenged sites of any of the naïve animals and at

					any of the challenged sites. Chlorophacinone does not fulfil the EU criteria for classification as a skin sensitiser.
3.5.	Germ cell mutagenicity	None		None	Chlorophacinone, does not fulfil the EU criteria for classification as a mutagenic substance.
3.6.	Carcinogenicity	None		None	Based on the available data, no classification for carcinogenicity for Chlorophacinone is proposed.
3.7.	Reproductive toxicity	None		None	Based on the available data, no classification for fertility for Chlorophacinone seems to be warranted.
3.8.	Specific target organ toxicity –single exposure	None		None	
3.9.	Specific target organ toxicity – repeated exposure	STOT RE 1		STOT RE 1	
3.10.	Aspiration hazard				
4.1.	Hazardous to the aquatic environment	According to Regulation (EC) No 1272/2008 and Regulation (EU) No 286/2011 Aquatic Acute 1 H400 Aquatic Chronic 1 H410	Acute M-factor 1 Chronic M-factor 1	Aquatic Acute 1 H400 Aquatic Chronic 1 H410 Acute M-factor 1 Chronic M-factor 1	
5.1.	Hazardous to the ozone layer				

¹⁾ Including specific concentration limits (SCLs) and M-factors

²⁾ Data lacking, inconclusive, or conclusive but not sufficient for classification

Labelling:

GHS pictogram: GHS06
GHS09

Signal word: Dgr, Warning

Hazard statements:

Oral:

H300: Fatal if swallowed

Dermal:

H310: Fatal in contact with skin

Inhalation:

H330: Fatal if inhaled

H372: Causes damage to organs (blood coagulation system, liver, kidney) through prolonged or repeated exposure

Aquatic acute 1: H 400 Very toxic to aquatic life

Aquatic chronic 1: H410 Very toxic to aquatic life with long lasting effects

Precautionary statements:

Prevention:

P260: Do not breathe dust/fume/gas/mist/vapours/spray

P270: Do not eat, drink or smoke when using this product

P271: Use only outdoors or in a well-ventilated area

P273: Avoid release to the environment

P280: Wear protective gloves/protective clothing/eye protection/face

protection

Response:

P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician

P302 + P350: IF ON SKIN: Gently wash with plenty of soap and water

P304 + P340: IF INHALED: remove victim to fresh air and keep at rest in a position comfortable for breathing

P391: Collect spillage

Storage:

P405: Store locked up

Disposal:

P501: Dispose of contents/container to...

Proposed notes assigned to an entry:

—

Table 4: Proposed classification according to DSD

Hazardous property	Proposed classification	Proposed SCLs	Current classification ¹⁾	Reason for no classification ²⁾
Explosiveness	Not explosive		-	
Oxidising properties	Not oxidising		-	
Flammability	Not highly flammable		-	Test material does not have a self ignition temperature below its melting point
Other physico-chemical properties	None			
Thermal stability	Apparently stable up to and beyond its melting point.			
Acute toxicity	T+; R26/27/28		T+; R27/28 T; R23	
Acute toxicity – irreversible damage after single exposure				
Repeated dose toxicity	T; R48/23/24/25		T; R48/24/25	
Irritation / Corrosion	None		None	
Sensitisation	None		None	
Carcinogenicity	None		None	
Mutagenicity – Genetic toxicity	None		None	
Toxicity to reproduction – fertility	None		None	
Toxicity to reproduction – development	None		None	
Toxicity to reproduction – breastfed babies. Effects on or via lactation	None		None	
Environment	N; R50/53		R50/53	

¹⁾ Including SCLs

²⁾ Data lacking, inconclusive, or conclusive but not sufficient for classification

Labelling:

Indication of danger: T⁺, N, Dangerous for the environment

R-phrases: R26/27/28 - R48/23/24/25 - R50/53

R26/27/28: Very toxic by inhalation in contact with skin and if swallowed

R48/23/24/25 Toxic: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed

R50 Very toxic to aquatic organisms

R53 May cause long-term adverse effects in the aquatic environment

S-phrases: (1/2)-36/37-45-53-60-61

S1/2: Keep locked up and out of reach of children

S36/37: Wear suitable protective clothing and gloves

S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible)

S53 Avoid exposure - obtain special instructions before use

S60 This material and its container must be disposed of as hazardous waste

S61 Avoid release to the environment. Refer to special instructions/safety data sheets

2 BACKGROUND TO THE CLH PROPOSAL

2.1 History of the previous classification and labelling

On basis of study results from studies presented in the dossier as a active substance in BPD, classification of chlorophacinone was proposed according to principles detailed in Annex VI of Council Directive 67/548/EEC (with amendments and adaptations).

The classification for human health effects of chlorophacinone is since May 2007 still under discussion. For anticoagulant rodenticides, regarding human health effects, a provisional classification with R61 was decided in November 2006 by the C & L, but without a final decision on the category to be used (Repr. Cat.1 or Repr. Cat. 2). The proposed classification for chlorophacinone for acute and repeated dose toxicity was agreed in May 2007. At that moment, the provisionally classification for reprotoxicity was not confirmed as the TC C& L decided to await further results from studies on anticoagulant rodenticides before finalising the discussion on reprotoxicity. Specific concentration limits for chlorophacinone are proposed, but there are still under consideration.

We sent on 23 March 2009 our Annex XV Intention. The proposal about classification included the risk phrase R61. However, the new OECD 414 study available for warfarin sodium affects the reasons for classification of chlorophacinone. This study addresses a regulatory request to investigate whether all AVK's should be classified as R61, based on read-across from warfarin sodium data.

The study carried out with warfarin sodium shows a definitive increase in incidence of subcutaneous and internal foetal haemorrhage (not seen in studies with chlorophacinone), foetal ocular effects and some indications of reduced ossification in skull bone at higher dose levels (see point 6). Similar studies have been completed with chlorophacinone which was not embryotoxic or teratogenic in rat and rabbit.

The adverse finding detected in a standard OECD 414 study for warfarin sodium, validates the negative findings in a similar study with chlorophacinone. Therefore, the phrase R61 is not warranted.

This MS is not proposing classification of chlorophacinone for reproduction (neither fertility nor development). Therefore, in principle, detail information of studies about reproduction were not required in this Annex XV. However it was considered necessary to include and discuss the available information about teratogenicity for chlorophacinone and compare with existing information on warfarin, due to the previous history of the proposal for R61 for all anti-vitamin K rodenticides by read across from the human embryotoxicity of warfarin. In this way RAC-ECHA, the Commission, Stakeholders and MS will be able to discuss this issue in the context of the proposals for all the antivit-K rodenticides.

2.2 Short summary of the scientific justification for the CLH proposal

Carries out an evaluation on an active substance in BP and the evaluation shows that the classification criteria are met.

Regarding the environmental effects, the lowest acute toxicity of chlorophacinone in aquatic organisms was of 0.45 mg a.s/l in fish R50. Chlorophacinone is not biodegradable under environmentally relevant conditions or expected to be biodegradable during sewage treatment processes (R 53).

According to Regulation (EC) No 1272/2008 since the aquatic toxicity is ≤ 1 mg a.s/l and the substance is not rapidly degradable, the substance is classified as Acute Category 1 and Chronic Category 1.

In respect of Regulation (EU) No 286/2011 the classification is Category Acute 1 and Category Chronic 1. Since there is only one NOEC available, a comparison was performed with that NOEC and the surrogate system. The most restrictive classification was chosen. With the algae NOErC = 0.72 mg a.s/l Category Chronic 2 should apply. On the other hand, applying the surrogate system, Category Chronic 1 should apply. This is the most restrictive one category. Conclusion: chlorophacinone is classified as Category Acute 1 and Category Chronic 1.

2.3 Current harmonised classification and labelling

Chlorophacinone is classified in Annex VI to Regulation (EC) No 1272/2008

Class of danger: T⁺, N

R Phrases:

R27/28: Very toxic in contact with skin and if swallowed

R23: Toxic by inhalation

R48/24/25 Toxic: Danger of serious damage to health by prolonged exposure in contact with skin and if swallowed.

R50/53: Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

S Phrases:

S(1/2): Keep locked up and out of reach of children

S36/37: Wear suitable protective clothing and gloves

S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible)

S60: This material and its container must be disposed of as hazardous waste

S61: Avoid release to the environment. Refer to special instructions/safety data sheets

2.3.1 Current classification and labelling in Annex VI, Table 3.1 in the CLP Regulation

<u>Classification</u>		<u>Labelling</u>			<u>Specific Conc. Limits, M-factors</u>	<u>Notes</u>
<u>Hazard Class and Category Code(s)</u>	<u>Hazard statement Code(s)</u>	<u>Pictogram, Signal Word Code(s)</u>	<u>Hazard statement Code(s)</u>	<u>Suppl. Hazard statement Code(s)</u>		
Acute Tox. 1 Acute Tox. 2 * Acute Tox. 3 * STOT RE 1	H310 H300 H331 H372(**)	GHS06 GHS08 Dgr	H310 H300 H331 H372 (**)			
Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09	H410			

2.3.2 Current classification and labelling in Annex VI, Table 3.2 in the CLP Regulation

<u>Classification</u>	<u>Labelling</u>	<u>Conc. Limits</u>	<u>Notes</u>
T+; R27/28 T; R23 T; R48/24/25	T+; N R 23 R 27/28 R 48/24/25 S: (1/2-)36/37-45		
N; R50/53	N R: 50/53 S: 60-61		

2.4 Current self-classification and labelling

2.4.1 Current self-classification and labelling based on the CLP Regulation criteria

GHS pictogram: GHS06; GHS08; GHS09

Signal word: Danger, Warning

Hazard statements:

Acute Tox. 1: H310 Fatal in contact with skin

Acute Tox. 2: * H300 Fatal if swallowed

Acute Tox. 3: * H331 Toxic if inhaled

STOT RE 1: H372(**) Causes damage top organs through prolonged or repeated exposure

Aquatic acute 1: H 400 Very toxic to aquatic life

Acute M-factor 1

Aquatic chronic 1: H410 Very toxic to aquatic life with long lasting effects

Chronic M-factor 1

Precautionary statements:

P260: Do not breathe dust/fume/gas/mist/vapours/spray

P270: Do not eat, drink or smoke when using this product

P271: Use only outdoors or in a well-ventilated area

P273: Avoid release to the environment

P280: Wear protective gloves / protective clothing / eye protection / face protection

P301 + P310: If swallowed: immediately call a poison center or a doctor/physician

P302 + P350: IF ON SKIN: Gently wash with plenty of soap and water

P304 + P340: IF INHALED: remove victim to fresh air and keep at rest in a position

comfortable for breathing

P391: Collect spillage

P405: Store locked up

P501: Dispose of contents/container to...

2.4.2 Current self-classification and labelling based on DSD criteria

Classification	as detailed in Directive 67/548/EEC
Class of danger	T+ N
R phrases	R27/28: Very toxic in contact with skin and if swallowed R23: Toxic by inhalation R48/24/25: Toxic: Danger of serious damage to health by prolonged exposure in contact with skin and if swallowed. R50/53: Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
S phrases	S(1/2): Keep locked up and out of reach of children S36/37: Wear suitable protective clothing and gloves S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible) S60: This material and its container must be disposed of as hazardous waste S61: Avoid release to the environment. Refer to special instructions/safety data sheets.

3 JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL

Carries out an evaluation on an active substance in BP and the evaluation shows that the classification criteria are met.

Part B.

SCIENTIFIC EVALUATION OF THE DATA


1 IDENTITY OF THE SUBSTANCE

1.1 Name and other identifiers of the substance

Table 5: Substance identity

EC number:	223-003-0
EC name:	-
CAS number (EC inventory):	-
CAS number:	3691-35-8
CAS name:	-
IUPAC name:	2-(2-(4-chlorophenyl)-2-phenyl-acetyl)indan-1,3-dione
CLP Annex VI Index number:	606-014-00-9
Molecular formula:	C ₂₃ H ₁₅ ClO ₃
Molecular weight range:	374.82

Structural formula:



1.2 Composition of the substance

Table 6: Constituents (non-confidential information)

Constituent	Typical concentration	Concentration range	Remarks
<u>Chlorophacinone</u> :	> 97.8% (w/w)		Chlorophacinone contains one optically active carbon and therefore exists as two enantiomers. The ratio of the enantiomers is provided in the confidential file

Current Annex VI entry:

Table 7: Impurities (non-confidential information)

Impurity	Typical concentration	Concentration range	Remarks
			Information on the impurities and additives in the technical grade active substance is confidential

Current Annex VI entry:

Table 8: Additives (non-confidential information)

Additive	Function	Typical concentration	Concentration range	Remarks
-				

Current Annex VI entry:

1.2.1 Composition of test material

Test material used in the **physical-chemical** studies:

	Method	Test-Material
Melting point	OECD 102 (≡ EEC A.1)	Batch M121, purity 99.74%
Boiling point	OECD 103 (≡ EEC A.2)	BatchM127, purity 99.77%
Density	OECD 109/CIPAC MT 3 (≡ EEC A.3)	Batch CLO 217, purity 99.85%
Vapour pressure	OECD104 (≡ EEC A.4)	Batch 11328, purity 100%
Henry's Law Constant	Calculation	Calculated from vapour pressure of 4.76×10^{-4} Pa and water solubility of 13.0 mg/L.
Appearance (Physical state, Colour,	Visual, Visual (Munsell colour system), Olfactory - ASTM D1292-	Batch CLO 217, purity 99.85%

CLH REPORT FOR [CHLOROPHACINONE]

Odour)	80	
Absorption spectra (IR, NMR, MS)	IR: - NMR: Proton and 13C NMR MS: HPLC- APCI MS All spectra are consistent with the structure of the active substance	Batch CLO ANA 479 purity not stated, Batch CLO432 purity not stated, Batch CLO432 purity not stated)
Solubility in water	OECD 105 (≡EEC A.6)	Batch M121, purity 99.74%
Dissociation constant	OECD 112	Batch M121, purity 99.74%
Solubility in organic solvents, including the effect of temperature on solubility	EPA 40 CFR 158 Subdiv.D, 63.-8 (≡EEC A.6 and OECD 105)	Batch CLO2022, purity 101%
Stability in organic solvents used in b.p. and identity of relevant breakdown products		Not applicable because the active substance as manufactured does not include an organic solvent and is not formulated in organic solution in the biocidal product.
Partition coefficient n-octanol/water - including effects of pH (5-9).	OECD 107 (≡ EEC A.8)	Batch M121, purity 99.74%
Thermal stability, identity of relevant breakdown products	OECD 113	Batch CLOM127, Purity 99.77%
Flammability, including auto-flammability and identity of combustion products	EEC A10 (flammability of solids)	Batch CLOM127, Purity 99.77%
Surface tension	EEC A5 OECD 115	Batch CLOM127, purity 99.77%
Explosive properties	EEC A14	Not explosive
Oxidising properties	EEC A17	

Test material used in the **(eco)-toxicological** studies:

	Method	Test-Material / Test Animals
Oral toxicity , LD50 study in: 1. rat 2. dog	US EPA Guideline 81-1. In accordance with EC Method B.1	1. Batch (E6619), purity 99.36% / Sprague Dawley Rat (IOPS-VAF) 2. Batch Lot # 217, purity 100.17% / Dogs (V Purebred Beagle)
Dermal toxicity , LD ₅₀ study in: 1. rabbits 2. range finding study in rabbits 3. range finding study in rabbits 4. rabbits	1. US EPA 81-1. Range-finding study in accordance with requirements of EC Method B.3. 2. EPA 81-1, Range-finding study in accordance with requirements of EC Method B.3.	Batch Lot #: CLOMO15, purity 100.36% / New Zealand White Rabbits

CLH REPORT FOR [CHLOROPHACINONE]

	<p>3. EPA 81-1. Range-finding study in accordance with requirements of EC Method B.3.</p> <p>4. FIFRA 40 CFR, Part 158, Subpart F Hazardous Evaluation: Human and Domestic Animals, 1984. EPA 81-1. In accordance with EC Method B.3.</p>	
Inhalation toxicity, LD₅₀ study in: rats	Pesticide Assessment Guidelines. Subdivision F. Hazard Evaluation Human and Domestic Animals, Series 81-3, EPA 540/9-84-014; 1984; EPA-81-2. In accordance with EC Method B.2	Batch CLO 2022, purity 101.0% / Albino rat
Dermal irritation	FIFRA 40 CFR, Part 158, Subpart F Hazardous Evaluation: Human and Domestic Animals, 1984. EPA 81-4 in accordance with EC Method B.4.	Batch Lot #: CLOM010, purity 99.88% / New Zealand White Rabbits
Eye irritation	US EPA Guideline 81-4. In accordance with EC Method B.5.	Batch Lot #: CLOM010 purity 99.88% / New Zealand White Rabbits
Skin sensitisation	Method in accordance with EC Method B.6.	Batch Lot #: CLOM010 purity 99.88% / Guinea pigs
Absorption, distribution, metabolism and excretion study: 1. Single oral dose study in the rat 2. Single oral dose study in the rat	The study was conducted prior to the availability of guidelines for this study type. However, methodology is similar to US EPA 85-1 guidelines.	<p>1. Chlorophacinone, Rozol LM-91 , Batch 117</p> <p>2. Non-radiolabelled batch – CLOM123 - Radiolabelled batch – SEL/1258-1, purity 99.58% / Rat (CrI:CD(SD)IGSBR)</p>
Repeated dose toxicity: Dermal: Rabbits (21 days) Dermal: Rabbits (21 days) Oral: Rats (11 to 16 weeks)	<p>FIFRA 40 CFR, Part 158, Subpart F Hazardous Evaluation: Human and Domestic Animals, 1984. EPA Pesticide Assessment Guidelines Subdivision F, Series 82-2, 1984. Dose range-finding study in accordance with requirements of EC Method B.9.</p> <p>EPA 82-2. In accordance with EC Method B.9</p> <p>EPA Pesticide Assessment Guidelines, Subdivision F, 82-1. Study design was in accordance with EC Method B.27.</p>	<p>Chlorophacinone (Lot # CLO 2022), purity 100%</p> <p>Chlorophacinone Lot No: 06691, purity 0.2%</p> <p>Chlorophacinone; Various lot numbers were identified in the Certificates of Analysis: E6071; E6072; E6073; E6074; E6079; E6086; E6091; E6093; E6098 for 100 mg/mL formulation; E6100; E6101; E6102; E6103; E6115; E6142 for 10 mg/mL formulation;</p>
In-vitro gene mutation in bacteria (<i>Bacterial reverse mutation test</i>)	The study was conducted according to EPA 84-2a and EC Method B13/14 test guidelines.	Chlorophacinone (Analysis No. 1750) O.F.No: 155, purity 99.8% / Salmonella typhimurium strains: TA

CLH REPORT FOR [CHLOROPHACINONE]

		98, TA 100, TA 1535, TA 1537, TA 1538 in culture suspension (about 10 ⁹ bacteria per ml)
In-vitro gene mutation in bacteria (<i>Bacterial reverse mutation test</i>)	The test design was based on that developed by Ames, B.N. and complied with the principles of the test detailed in EC Method B.13/14. US EPA 84-2.	Chlorophacinone (Lot # CLO 2022), purity 101% - Salmonella typhimurium strains: TA 98, TA 100, TA 1535, TA 1537, in culture suspension (about 10 ⁹ bacteria per ml) - Escherichia coli strains: WP2uvrA
In-vitro gene mutation in mammalian cells (Induction of gene mutation in CHO cells)	The study was performed according to guidelines OECD 476 (1984; EEC 67/548 (1967) – 79/831(1979) – 83/467 (1983 – 84/449 (1984)) – 88/302 (1988). EPA 84-2. In accordance with EC Method B.17.	Chlorophacinone (Batch No: CLOM 027) / <u>mammalian cell lines</u> : Chinese Hamster Ovary (CHO)
In-vitro gene mutation in mammalian cells (<i>In-vitro</i> mammalian chromosome aberration test)	OECD Guideline 473, US EPA Guideline 84-2. In accordance with EC Method B.10.	Chlorophacinone; Batch Lot No: CLO 2022, purity 96.82% / <u>mammalian cell lines</u> : human lymphocytes cultured from healthy human donor
In-vivo mutagenicity (bone marrow)	The test was conducted in accordance with the EPA 84-2 and EC Method B.12.	Chlorophacinone (Lot # CLO2022), Purity 101.00% / Rats VAF CD Sprague- Dawley
Carcinogenicity in rats	Justification for non-submission of data	
Teratogenicity study: 1. In rats 2. in rabbits	The study was conducted according to the FIFRA testing guidelines (EPA 83-3, 1988) and EC Method B.31.	1. Batch Lot # CLO 2022, purity 99.77% 2. Lot # CLO 2022 purity 101.00% / Rabbits New Zealand White

Table 9: Summary of physico - chemical properties

Property	Value	Reference	Comment (e.g. measured or estimated)
State of the substance at 20°C and 101,3 kPa	Powder Pale yellow Odourless		
Melting/freezing point	143 °C	This information is confidential. See references 12 and 16 of confidential annex.	Capillary tube method
Boiling point	Melted at 140°C followed by decomposition without boiling that started at 250°C. pressure: atmospheric, air.	This information is confidential. See reference 48 of confidential annex.	Differential scanning calorimetry and capillary tube test
Relative density	Density = 1.4301 ± 0.01385 g/mL	This information is confidential. See references 16 and 39 confidential annex.	
Vapour pressure	4.76 x 10 ⁻⁴ Pa temperature: 22.8°C	This information is confidential. See reference 13 of confidential annex.	Gas saturation method
Surface tension	68.9 mN/m at 20.6°C at 90% saturated solution	This information is confidential. See reference 30 of confidential annex.	This value is greater than 60 mN/m and is therefore not considered surface active.
Water solubility	Water: 13 µg/mL pH 4: 1 µg/mL pH 7: 344 µg/mL pH 10: 459 µg/mL temperature: 20°C	This information is confidential. See references 14 and 17 of confidential annex.	Column elution Column elution Column elution Column elution Test substance shown to be unstable at pH4. Analysis by HPLC.
Partition coefficient n-octanol/water	Log P _{ow} 1.93 (no pH control, 23°C) pH~4: Log P _{ow} 3.08 temperature: 23°C pH~7: Log P _{ow} 2.42 temperature: 23°C pH~9: Log P _{ow} 2.57 temperature: 23°C	This information is confidential. See references 18 and 33 of confidential annex.	
Flash point			Not required for a solid active substance.
Flammability	Not highly flammable	This information is confidential. See	

		reference 28 of confidential annex.	
Explosive properties	Not explosive	This information is confidential. See reference 31 of confidential annex.	Theoretical assessment in compliance with EEC A14
Self-ignition temperature	Test material does not have a self ignition temperature below its melting point.	This information is confidential. See reference 29 of confidential annex	
Oxidising properties	Not oxidising	This information is confidential. See reference 32 of confidential annex.	Theoretical assessment in compliance with EEC A17
Granulometry			
Stability in organic solvents and identity of relevant degradation products			Not applicable because the active substance as manufactured does not include an organic solvent and is not formulated in organic solution in the biocidal product.
Dissociation constant	pKa = 8.0	This information is confidential. See reference 18 of confidential annex.	Report describes the results as marginal as the solubility of chlorphacinone is near the limit of applicability for pKa and a co-solvent was required. This would introduce an inaccuracy into the determination.
Viscosity			Not applicable because the active substance is a solid.

2 MANUFACTURE AND USES

2.1 Manufacture

The main quantitative method for the determination of chlorphacinone in technical chlorphacinone is a titration. The method of manufacture is confidential.

2.2 Identified uses

MG03: Pest control. Product type 14. (Rodenticide)

The content of chlorphacinone in the typical products is 0.005%.

3 CLASSIFICATION FOR PHYSICO-CHEMICAL PROPERTIES

Table 10: Summary table for relevant physico-chemical studies

Method	Results	Remarks	Reference
Melting point: OECD 102 (≡ EEC A.1)	143.0°C pressure: atmospheric	Capillary tube method	Kramer and Marion, 2002a
Boiling point: EEC A.2 (OECD 103)	Melted at 140°C followed by decomposition without boiling that started at 250°C. pressure: atmospheric, air.	Differential scanning calorimetry and capillary tube test	Tognucci, 2002
Relative density: OECD 109/CIPAC MT 3 (≡ EEC A.3)	Density = 1.4301 ± 0.01385 g/mL conducted at 20 °C		Pesselman, 1990a
Vapour pressure: OECD 104 (≡ EEC A.4)	Vapour pressure = 4.76 x 10 ⁻⁴ Pa temperature: 22.8°C	Gas saturation method	Hoffman, 1988b
Appearance: Physical state: Visual Colour: Visual (Munsell colour system) Odour: Olfactory - ASTM D1292-80	Powder Pale yellow 5Y (9/6) Odourless		Pesselman, 1990b Pesselman, 1990c Pesselman, 1990d
Spectra active substance: UV/VIS – No Method IR – No Method NMR – Proton and 13C NMR MS – HPLC- APCI MS	All spectra are consistent with the structure of the active substance		Queche, 1999
Solubility in water including effect of pH OECD 105 (≡EEC A.6)	<ul style="list-style-type: none"> • Water: 13 µg/mL • pH 4: 1 µg/mL • pH 7: 344 µg/mL • pH 10: 459 µg/mL temperature: 20°C	Column elution Column elution Column elution Column elution Test substance shown to be unstable at pH4. Analysis by HPLC.	Kramer and Marion, 2002b

<u>Dissociation content</u> OECD 112	pKa = 8.0	Report describes the results as marginal as the solubility of chlorphacinone is near the limit of applicability for pKa and a co-solvent was required. This would introduce an inaccuracy into the determination.	Kramer and Marion, 2002c
<u>Solubility in organic solvents</u> EPA 40 CFR 158 Subdiv.D, 63.-8 (≡EEC A.6 and OECD 105)	Hexane: 854 mg/L Methanol: 786 mg/L temperature: 25°C	Shake flask method Shake flask method	Pesselman, 1991
<u>Partition coefficient n-octanol / water</u> OECD 107 (≡ EEC A.8)	pH 4: Log Pow 3.08 pH 7: Log Pow 2.4 pH 9: Log Pow 2.57 temperature: 23°C	Shake flask method	Kramer and Marion, 2002c
<u>Stability in the air, photo-chemical degradation, identity of breakdown product(s)</u> OECD 113	Apparently stable up to and beyond its melting point.	Tested using differential scanning calorimetry in an air atmosphere and by capillary tube melting point method.	Lindemann, 2004a
<u>Flammability</u> EEC A10 (flammability of solids) EEC A16	Not highly flammable Test material does not have a self ignition temperature below its melting point.		Lindemann, 2004b Lindemann, 2004c
<u>Surface tension</u> EEC A5 - OECD 115	68.9 mN/m at 20.6°C at 90% saturated solution	This value is greater than 60 mN/m and is therefore not considered surface active.	Lindemann, 2003d
<u>Explosive properties</u> EEC A14	Not explosive	Theoretical assessment in compliance with EEC A14	Lindemann, 2003e
<u>Oxidizing properties</u> EEC A17	Not oxidising	Theoretical assessment in compliance with EEC A17	Lindemann, 2003f
<u>Reactivity towards container material</u>	Chlorophacinone has been stored in a range of containers (such as plastic bags in metallic containers and plastic containers). No interaction between the active ingredient and the container materials has been observed in the past 20 years of production. Based on results in use and examination of the chemical structure, there are considered to be no problems with reactivity of the active substance towards the container material.		

3.1 *[Insert hazard class when relevant and repeat section if needed]*

None

3.1.1 **Summary and discussion of****3.1.2** **Comparison with criteria****3.1.3** **Conclusions on classification and labelling**

Chlorophacinone is thermally stable up to 143°C, its melting point. It is not classified as highly flammable and does not undergo self ignition below its melting point. It is not explosive nor does it have oxidising properties. There is no record that it has reacted with any storage container during many years of industrial production. Therefore, there are no hazards associated with normal use of the active substance. The substance is not classified for physico-chemical properties.

4 **HUMAN HEALTH HAZARD ASSESSMENT**

The active substance belongs to a group of substances, the anti-vitamin K rodenticides (AVKs) where the mode of action is well known. A summary of the mode of action, taken from the WHO IPCS Environmental Health Criteria 175 Anticoagulant Rodenticides (WHO Geneva, 1995 ISBN 92 4 157175 6) is presented here.

Anticoagulant rodenticides function by inhibiting the ability of the blood to clot at the site of a haemorrhage, by blocking the regeneration of vitamin K in the liver. Death is due to haemorrhage.

The molecule has significant structural similarity to the forms of vitamin K. This structural similarity is responsible for the ability to interfere with i.e. block the enzymes used to regenerate vitamin K. The progressive blocking of the regeneration of vitamin K will lead to an increasing probability of a fatal haemorrhage. In general terms, a progressive intake of anticoagulants is causing death.

Blood clots form when the soluble protein fibrinogen, normally present in the blood, is converted by the enzyme thrombin (factor IIa) to the insoluble fibrous protein fibrin, which binds platelets and blood cells to form a solid mass referred to as a blood clot, sealing the site of the haemorrhage and preventing further blood loss. Thrombin is formed at the site of injury from prothrombin (factor II) which is present in the blood. Conversion of prothrombin to thrombin occurs via the coagulation cascade, in which the blood clotting factors are employed. Without these blood factors clotting cannot take place, and the haemorrhage will not be controlled by clot formation. If the blood vessel is large and/or serves a vital organ, the haemorrhage will be fatal. The synthesis of a number of blood coagulation factors is dependent upon vitamin K hydroquinone, which is the active co-enzyme, and its oxidation to vitamin K 2,3-epoxide provides the energy required for the carboxylation reaction where glutamate (Glu) in the precursor is converted to γ -carboxyglutamate (Gla) to make the activated clotting factor. The anticoagulant rodenticide blocks the regeneration of vitamin K 2,3-epoxide to vitamin K hydroquinone. The Glu→Gla conversion does not take place.

4.1 **Toxicokinetics (absorption, metabolism, distribution and elimination)**

The metabolism studies in rats (draft CAR on Chlorophacinone, Doc III-A, 6.2-01, 6.2-02), showed that Chlorophacinone is rapidly absorbed following oral administration. Using radioactive Chlorophacinone it is rapidly absorbed and that 90% radioactivity is excreted in faeces within 48

hours and 100% in 4 days, most as metabolized compounds, with only less than 1% in urine and no excretion via expired air. Compound is absorbed, enters the enterohepatic circulation and then is excreted through the faeces.

Relatively short plasma half-life (10.2 hours), with 100% of the administered material excreted within 4 days after a single low dose. Higher doses (2 mg/kg) showed that a 168 hours excretion is incomplete with 8% of dose was still presented in the carcass.

In a *in vitro* test dermal penetration with human skin, Chlorophacinone showed rapid absorption but with minimal total absorption. Total absorption was estimated to be 1.7% for the human including radioactivity measured in receptor fluid, tape stripping and residual skin values. (Draft CA report on Chlorophacinone, Doc III-A, 6.2-03).

4.1.1 Non-human information

Two toxicokinetics studies are available. The first one (A6.2-01) describes the absorption, distribution and excretion using radioactive chlorophacinone and was demonstrated that it is rapidly absorbed and that 90% radioactivity is excreted in faeces within 48 hours most as metabolized compounds, with only less than 1% in urine. In the second study, metabolites are identified and demonstrated that about 19 % of faecal radioactivity is unchanged parent compound. Two main metabolites were identified as hydroxylated metabolite. A metabolite presented as 12% of faecal radioactivity was not identified as well as other minor metabolites. After 168 hours excretion was incomplete and about 8% was detected in carcasses.

First toxicokinetic study (A6.2-01): Animals were dosed orally with 1.0 to 1.43mg/animal, either single dose, or three consecutive daily doses.

Chlorophacinone seems to have a rapid absorption. The single dose studies indicate the $T_{1/2} = 10.2$ hours with the maximum blood concentration at 4 hours after administration. Tissue residue studies on animals sacrificed 48 hours following a single dose show that the liver is by far the organ with the highest concentrations of radioactivity present. The following is the kidneys with the concentration of radioactivity five times lower than in the liver at 4 hours and approximately 2.8 times lower after 48 hours. After 3 dose administration, the concentrations are approximately twice the concentration after a single dose at 4 to 6 hours.

Excretion of 90 % of the radioactivity is recovered from faeces within 48 hours after oral administration and 100 % within 4 days. The urinary and CO_2 elimination was less than 1 %. Biliary excretion at the end of 8 hours is approximately 26% of the administered radioactivity. The highest tissue concentration is found in the liver.

It is concluded that the compound is absorbed, enters the enterohepatic circulation and then is excreted through the faeces via bilis.

Extracted faeces and bile in TLC indicated that the material is mainly excreted as metabolized compounds and that unchanged parent accounted for only a small component of the faecally eliminated radioactivity but the proportions of unchanged substance and metabolites were not quantified in this study. Moreover, no metabolite identification was undertaken in this study.

Second study to identify metabolites (A6.2-02): In this study, dosing rats with 2 mg/kg b, excretion was incomplete 168 hours after a single oral dose at 2 mg ^{14}C -chlorophacinone /kg bw to male rats with 8% of dosed radioactivity residues found in carcass at necropsy.

However in a previous study, excretion was reported estimated to be 100%, 96 hours after a single dose of 1 mg/kg bw. The discrepancy is not explained.

Faecal elimination was major route of excretion, urine accounted for less than 1% of administered dose with 91 % recovery of total radioactivity. A 77.56 % of total dosed radioactivity was recovered in faeces.

About 19.6% of the faecal radioactivity was from unchanged chlorophacinone (equivalent to 15% of dosed radioactivity). Two major metabolites represented for 45% of faecal radioactivity (equivalent to 36.2 % of total dosed radioactivity)

The three identified excreted compounds in faeces (parent compound plus monohydroxylated metabolites) accounted for 66% of the faecal radioactivity, being there remaining 34% due to other minor unidentified metabolites.

It is important to note that a peak representing 12.49 % of assigned peaks (representing about 8 % of dosed radioactivity) was detected but not identified.

In conclusion:

- The *in vitro* topical application of ¹⁴C-Chlorophacinone as a tracking powder formulation or wheat flour bait to human split thickness skin samples maintained *in vitro* resulted in similar rapid rates of absorption with radioactivity appearing within 1.7 or 0.25 hours respectively but absorption was minimal and less than 0.1% (powder) or 0.5 % (bait) were detected in the receptor fluid.

4.1.2 Human information

An *in vitro* human dermal penetration study (Section A6.2-03) was performed on a moistened 50 mg/Kg wheat bait formulation and on a 2g/kg tracking powder formulation. The formulations were spiked with radiolabelled Chlorophacinone. Skin samples were exposed for 6 hours and washed with soap. Receptor fluid was collected during the exposure period and for 18 hours post exposure. At 6 h post application, any residual formulation was washed from the surface of the skin. Tape stripping was applied to remove epidermis and residual skin solubilised. The total radioactivity detected in receptor fluid, plus tape strips and residual skin was used as an estimation of total absorption.

The *in vitro* topical application of ¹⁴C-Chlorophacinone as a tracking powder formulation or wheat flour bait to human split thickness skin samples maintained *in vitro* resulted in similar rapid rates of absorption with radioactivity appearing within 1.7 or 0.25 hours respectively but absorption was minimal and less than 0.1% (powder) or 0.5 % (bait) were detected in the receptor fluid.

Total absorption of ¹⁴C- Chlorophacinone (tracking powder) including receptor fluid (0.1%), residual skin levels (1.0%) and tape stripping values (0.3%) was 1.4%. The study with wheat flour formulation showed 0.44 % in receptor fluid, and 0.236% in tape strips (total 0.676%) and residual skin values was not used due to high adhesion of particles not eliminated by washing; if it is assumed that a similar residual skin value (1.0%) is appropriate then total absorption is circa 1.7%. This last value was adopted as the best estimation of dermal absorption.

In conclusion:

- Total absorption in human skin is estimated to be not more than 1.7%., deduced from an *in vitro* test using topical application of ¹⁴C-Chlorophacinone as a tracking powder formulation or wheat

flour bait to human split thickness skin samples maintained *in vitro*, considering total absorption including radioactivity measured in receptor fluid, tape stripping and residual skin values.

4.1.3 Summary and discussion on toxicokinetics

Oral absorption	<p>Chlorophacinone is rapidly absorbed following oral administration.</p> <p>Using radioactive Chlorophacinone, it is rapidly absorbed and 90% radioactivity is excreted in faeces within 48 hours and 100% in 4 days, most as metabolized compounds, with less than 1% in urine. The compound is absorbed, enters the enterohepatic circulation and then is excreted through the faeces</p>
Plasma half-life	<p>Relatively short plasma half-life (10.2 hours), with 100% of the administered material excreted within 4 days after a single low dose.</p> <p>Higher doses (2 mg/kg) showed that at 168 hours excretion is incomplete with 8% of dose still present in the carcass.</p>
Elimination	<p>The elimination was mainly via faeces, with little or no urinary excretion (< 1%), and no excretion via expired air. Most faecal excretion was as metabolised compounds accompanied with unchanged parent compound (19.6% of the faecal radioactivity, equivalent to 15% of dosed radioactivity). Two major metabolites represented for 45% of faecal radioactivity (equivalent to 36.2 % of total dosed radioactivity) as hydroxylated metabolites, with some “minor” unidentified metabolites.</p>
Metabolites	<p>The three identified excreted compounds in faeces (parent compound plus monohydroxylated metabolites) accounted for 66% of the faecal radioactivity, being the remanding 34% due to other minor unidentified metabolites.</p> <p>Two main metabolites were identified as hydroxylated metabolised, one in the indandione group and the other in the biphenyl portion of the molecule. The two analogues constituted 46% of faecal radioactivity (36.2% of administered dose)</p> <p>It is important to note that a peak representing 12.49 % of assigned peaks (representing about 8 % of dosed radioactivity) was detected but not identified.</p> <p>The industry argues that "none of the metabolites identified for indandione derivatives used as rodenticides have been shown to be toxicologically significant". However no data is presented to justify this statement. So there are not appropriate data to confirm if the metabolites are or not less toxic than the parent compounds.</p>
Dermal penetration	<p>Total absorption in human skin is estimated to be not more than 1.7%, deduced from a test using topical application of ¹⁴C-Chlorophacinone as a tracking powder formulation or wheat flour bait to human split thickness skin samples maintained <i>in vitro</i>, considering total absorption including radioactivity measured in receptor fluid, tape stripping and residual skin values.</p>

4.2 Acute toxicity

Table 11: Summary table of relevant acute toxicity studies

Method	Results	Remarks	Reference
<u>ORAL</u> EPA 81-1 Number of animals/Sex/Dose: <ul style="list-style-type: none"> • Rat Sprague-Dawley IOPS- VAF; 10 male/group, 10 female/group • Single dose at 0, 2, 3.2, 5.2, 8.2, 13.2 and 21 mg/kg bw. Post exposure period, 21 days 	<ul style="list-style-type: none"> • Male: 3.15 mg/kg (1.48 - 6.68) • Female: 10.95 mg/kg (6.46 - 18.57) • <u>Combined: 6.26 mg/kg</u> (3.96 - 9.89) Mortalities mainly on the 4 th and 9 th day after treatment. Mortalities in males were observed from the lowest dose (4 males died at 2 mg/kg bw and 6 at 3.2 mg/kg bw)	<ul style="list-style-type: none"> • Definitive rat study • High mortality in males at all doses • Male were 3 times more sensitive than females 	Mally C., Porret-Blanc G. (1988)
<u>DERMAL</u> EPA 81-1 Number of animals/Sex/Dose: <ul style="list-style-type: none"> • Rabbit, New Zealand White; 2 male/group • Applied to 10% body surface at 100, 50, 10, 5 and 1 mg/kg for 24 hours 	Male LD ₅₀ 0.329 mg/kg. Mortalities occurred by days 16 to 19 of post treatment period.		Lilja H.S., (1990d)
<u>INHALATION</u> EPA 81-3 Number of animals/Sex/Dose: <ul style="list-style-type: none"> • Albino Rat, Sprague-Dawley; 7/8 male/group, 7/9 female/group • Nose-only exposure at dose levels of 1.33, 10.3, 11.5 and 14.5 µg/L 	<ul style="list-style-type: none"> • Male: 7.0 µg/L (0.83-59.0) • Female: 12.0 µg/L (7.80-18.0) • Combined: 9.3 µg/L (2.30-38.0) 		Holbert M.S., (1991)

Only the relevant or key studies have been included here. For the rest of studies, please see the CAR.

4.2.1 Non-human information

4.2.1.1 Acute toxicity: oral

Oral acute toxicity in rats

The critical LD₅₀ for oral dosing in rats were 3.15 mg/kg bw for male rats. Male were more sensitive than females with LD₅₀ at least 3 times lower in males.

- Male: 3.15 mg/kg (1.48 - 6.68) (< 5 mg/Kg)
- Female: 10.95 mg/kg (6.46 - 18.57)
- Combined: 6.26 mg/kg (3.96 - 9.89) (Not < 5 mg(Kg))

High mortality was observed in males at all doses, including the lowest doses (4 of 10 males died at 2 mg/kg bw and 6 at 3.2 mg/kg bw), and so, the confidence interval goes down to 1.48 mg/kg for LD₅₀ in males. Mortalities occurred mainly on the 4th and 9th day after treatment. Death was a result of internal haemorrhage, which is the known mode of action of anticoagulant active substance.

A pre-test study was performed in dogs with oral dose of 4.0, 25, 50 mg/kg and the main study at 2, 4.6, 10.8 and 25 mg/kg bw. Dogs were fed with a vitamin K deficient diet. (Disturbance in the main effects?). High mortality occurred at all doses in the pre-test study were all animals died and in the main study all males died at all doses and 3/4 females died at 2, 4.6, and 25 mg/kg; and all females at 10.8 mg/kg.

4.2.1.2 Acute toxicity: inhalation

An acute inhalation toxicity study was conducted on albino rats. The animals were exposed nose-only to a dust with $\geq 25\%$ of particle size under 1micron generated from the test material (fine powder) for four hours at dose levels of 1.33 $\mu\text{g/L}$, 10.3 $\mu\text{g/L}$, 11.5 $\mu\text{g/L}$, and 14.5 $\mu\text{g/L}$.

Clinical signs of poisoning were evident only in animals that died - activity decrease, ataxia, blanching, apparent bleeding from ears, and other. The deaths were considered stress-related, animals showed no clinical signs of haemorrhage or pathology findings at necropsy as observed in oral or dermal exposure.

Mortality was as follows 0/14, 6/14, 13/14 and 5/11 at 1.33, 10.3, 11.5 and 14.5 $\mu\text{g/L}$ group, respectively. Gross pathology: Chromodacryorrhea, diarrhea, lacrimation, nasal discharge and polyuria, apparent bleeding from ears, discoloration of vital organs, lungs swollen, discoloration of the contents of the gastrointestinal tract and bladder, gastrointestinal tract distended with gas, materials in pleural and abdominal cavity, testes drawn into the abdominal cavity..

The acute inhalation LC₅₀ with 95 % confidence interval for technical Chlorphacinone when administered undiluted as a dust to albino rats were calculated to be:

Males – 7.00 $\mu\text{g/L}$ (0.83-59.0);

Females – 12.00 $\mu\text{g/L}$ (7.80-18.0);

Males and Females – 9.30 $\mu\text{g/L}$ (2.30-38.0) (0.0093 mg/L <LC₅₀ 0.05 mg/L for dust)

The critical LD₅₀ values in males showed a high uncertainty with a wide confidence interval. The high uncertainty is probably due to the observation that high mortality (6 out of 14) occurred from the second to the fourth dose level and short intervals of dose levels were applied between the different groups from the second to the highest dose level.

4.2.1.3 Acute toxicity: dermal

In a range finding study in rabbits dosed in the range of 1 to 100 mg kg/bw all animals died during days 6 to 11 post-treatment while in other study, in the range of 0.01 to 1 mg/kg bw no animal died. In another range finding study and in the main study, mortalities occurred in the range of 16 to 19 days after application.

In the main study, high but limited mortality was observed at all dose levels tested, including the lowest dose of 0.25 mg/kg bw: 9/10 by day 18 (at 0.25 mg/kg bw); 6/10 by day 16 (0.50 mg/kg bw) and 4/10 by day (0.25 mg/kg bw).

Signs of toxicity were limited to lethargy, abdominal breathing, pale ears and eyes, bleeding from the nostrils, discharge from the nostrils, watery stool, tachypnea and somnolence. No erythema and oedema, following 24 hours of exposure, was observed. Various lesions associated with internal haemorrhage were observed including abdominal and thoracic haemorrhages, pale lungs with large dark red foci, pitted kidneys, blood in urine, blood clots surrounding heart, loose stools mixed with blood, haemorrhages in the digestive and urogenital systems.

It is concluded that dermal acute exposure of Chlorophacinone elicited limited lethality at all dose levels enabling a determination of the dermal LD₅₀ of 0.329 mg/kg in the acute toxicity study rabbits.

4.2.1.4 Acute toxicity: other routes

-

4.2.2 Human information

4.2.3 Summary and discussion of acute toxicity

Chlorophacinone was very toxic to rats with the oral combined LD₅₀ of **6.26 mg/kg**.

Chlorophacinone was also acutely toxic to rabbit by dermal administration (**LD₅₀ of 0.329 mg/kg**) and by inhalation in rats (nose only: **LC₅₀: 9.3 µg/l** for males-females)

Therefore, Chlorophacinone is acutely toxic by the oral, dermal and inhalation routes. Death was a result of internal haemorrhage, which is the declared mode of action of the active substance.

4.2.4 Comparison with criteria

A. CLP Regulation:

Inhalat - Acute Tox. 1, (LC₅₀=0.0093 mg/L < 0.05 mg/L)
Dermal - Acute Tox. 1, (LD₅₀= 0.329 mg/Kg) (<50 mg/Kg)
Oral - Acute Tox. 2, (LD₅₀=6.26) (= range 5-50 mg/Kg)

“Fatal if inhaled, if contact with skin and if swallowed”.

B. DSD:

Class of danger: T+

R-phrases: **R26/27/28**: Very toxic by inhalation in contact with skin and if swallowed

4.2.5 Conclusions on classification and labelling

Classification:

<u>Hazard Class and Category Code(s)</u>	<u>Hazard Statement Code(s):</u>
Acute Tox. 1	H330
Acute Tox. 1	H310
Acute Tox. 2	H300

Labelling:

<u>Pictogram, Signal Word Code(s)</u>	<u>Hazard statement Code(s)</u>	<u>Suppl. Hazard statement Code(s)</u>
GHS06; Danger	H330: Fatal if inhaled H310: Fatal in contact with skin H300: Fatal if swallowed	

Precautionary statements:

Prevention:

P260: Do not breathe dust/fume/gas/mist/vapours/spray

P270: Do not eat, drink or smoke when using this product

P271: Use only outdoors or in a well-ventilated area

P280: Wear protective gloves/protective clothing/eye protection/face protection

Response:

P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician

P302 + P350: IF ON SKIN: Gently wash with plenty of soap and water

P304 + P340: IF INHALED: remove victim to fresh air and keep at rest in a position comfortable for breathing

Storage:

P405: Store locked up

Disposal:

P501: Dispose of contents/container to...

4.3 Specific target organ toxicity – single exposure (STOT SE)**4.3.1 Summary and discussion of Specific target organ toxicity – single exposure****4.3.2 Comparison with criteria****4.3.3 Conclusions on classification and labelling****4.4 Irritation****4.4.1 Skin irritation**

Table 12: Summary table of relevant skin irritation studies

Method	Results	Remarks	Reference
Skin irritation (rabbit) EPA 81-4	Non irritant Average score 24, 48, 72 h <ul style="list-style-type: none"> ▪ Erythema: 0.00 for non-abraded skin ▪ Oedema: 0.00 for non-abraded skin 	Reversibility yes/no: No effects therefore not applicable	Lilja H.S., (1989a)

4.4.1.1 Non-human information**4.4.1.2 Human information****4.4.1.3 Summary and discussion of skin irritation**

The test substance's average score or irritant properties for all animals at 24, 48 and 72 h are 0 for erythema and oedema. Chlorophacinone does not fulfil the EU criteria for classification as a skin irritant.

4.4.1.4 Comparison with criteria**4.4.1.5 Conclusions on classification and labelling**

Chlorophacinone does not fulfil the EU criteria for classification as a skin irritant.

4.4.2 Eye irritation

Table 13: Summary table of relevant eye irritation studies

Method	Results	Remarks	Reference
Eye irritation (rabbit) EPA 81-4	Chlorophacinone does not meet EU criteria for classification as an eye irritant. Average Score over 24, 48, 72 h for : <ul style="list-style-type: none"> ▪ Cornea reaction: 0.00 ▪ Iris reaction: 0.00 ▪ Conjunctiva redness : <ul style="list-style-type: none"> ▪ Redness 0.00 ▪ swelling: 0.00 	Reversibility yes/no : No effects therefore not applicable	Lilja H.S., (1989b)

4.4.2.1 Non-human information

4.4.2.2 Human information

4.4.2.3 Summary and discussion of eye irritation

The test substance's average score for all animals at 24, 48 and 72 h is 0 for the iris and cornea, and for chemosis and redness of the conjunctiva. Chlorophacinone does not fulfill the EU criteria for classification as an eye irritant.

4.4.2.4 Comparison with criteria

4.4.2.5 Conclusions on classification and labelling

Chlorophacinone does not fulfil the EU criteria for classification as an eye irritant.

4.4.3 Respiratory tract irritation

No study available. In the acute inhalation study, it was stated there was no evidence of respiratory tract irritation following a 4 h nose only exposure.

4.4.3.1 Non-human information

4.4.3.2 Human information

4.4.3.3 Summary and discussion of respiratory tract irritation

4.4.3.4 Comparison with criteria

4.4.3.5 Conclusions on classification and labelling

4.5 Corrosivity

Chlorophacinone does not fulfil the EU criteria for classification as a skin and eye irritant.

4.5.1 Non-human information

4.5.2 Human information

4.5.3 Summary and discussion of corrosivity

4.5.4 Comparison with criteria

4.5.5 Conclusions on classification and labelling

4.6 Sensitisation

No signs of irritation were observed. Test substance not classified as a sensitizer.

4.6.1 Skin sensitisation

Table 15: Summary table of relevant skin sensitisation studies

Method	Results	Remarks	Reference
Skin sensitization EPA 81-6	<ul style="list-style-type: none"> - Buehler test design, 10 test and 5 control animals. Six, 6 hour exposure, topical induction applications followed by topical challenge. - No indications of delayed contact hypersensitivity among guinea pigs subject to an induction and challenge regimen with a sublethal dose. - No signs of irritation were observed. Test substance not classified as a sensitizer. 		Shapiro R., (1990)

4.6.1.1 Non-human information

4.6.1.2 Human information

4.6.1.3 Summary and discussion of skin sensitisation

4.6.1.4 Comparison with criteria

4.6.1.5 Conclusions on classification and labelling

Conclusion for classification: Chlorophacinone is not classified as a skin sensitizer.

4.6.2 Respiratory sensitisation

No information

4.6.2.1 Non-human information

4.6.2.2 Human information

4.6.2.3 Summary and discussion of respiratory sensitisation

4.6.2.4 Comparison with criteria

4.6.2.5 Conclusions on classification and labelling

4.7 Repeated dose toxicity

Table 17: Summary table of relevant repeated dose toxicity studies

Method	Results	Remarks	Reference
<p>Oral – Rat - EPA 83-3</p> <p>Number of animals/Sex/Dose:</p> <ul style="list-style-type: none"> • Rat Sprague Dawley OFA IOPS Both sexes, 10 per group. • 5 µg/kg bw daily for 11 weeks; 10, 20, 40, 80 or 160 µg/kg bw daily for up to 16 weeks 	<p>Rat (90 day oral administration)</p> <p>No target organs were identified. The mode of action for anticoagulant rodenticides is well characterised. The critical effect is death arising from persistent or severe haemorrhage. The clinical findings in the study were indicative of internal haemorrhagic events and were consistent with the established pattern of increasing prothrombin times associated with increasing severity of bleeding for orifices or abrasions, pallor, ataxia or weakness/limb paralysis and breathing difficulty. Death rapidly followed development of signs and necropsy confirmed presence of haemothorax and haemoperitoneum among other diffuse, non-specific haemorrhages and haematoma formation.</p>	<p>Lowest relevant oral NOAEL / LOAEL</p> <p>LOAEL = 0.010 mg/kg b.w. /day NOAEL = 0.005 mg/kg b.w. /day (11 weeks exposure)</p> <p>(Some uncertainty due to shorter time at the dose of 5 µg/kg b.w. /day and no prothrombin time determination at this dose)</p>	<p>Mally C., Porret-Blanc G., Lorgue G. (1984)</p>
<p>Dermal – Rabbit - EPA 83-3</p> <p>Number of animals/Sex/Dose:</p> <ul style="list-style-type: none"> • Rabbit New Zealand, 10 (5 M 5 F) per group • Dosage levels were 0.08 mg/kg/day, 0.40 mg/kg/day, and 2.00 mg/kg/day applied as 0.2% w/w tracking powder 	<p>Rabbit (15 day dermal administration, 5 days/week for 3 weeks)</p> <p>Widespread non-specific haemorrhage was the primary cause of death among rabbits dosed with a 2% formulation of chlorophacinone. Necropsy also revealed centrilobular liver necrosis. In-life signs of haemorrhage were confirmed by necropsy observations of free fluid in many body cavities and pale organs. Increased prothrombin times were measured in-life as an indicator of progressive failure of the clotting cascade arising from non-replenishment of Vitamin K in the liver of intoxicated animals.</p>	<p>Lowest relevant dermal NOAEL / LOAEL</p> <p>LOAEL 0.40 mg/kg/day NOAEL 0.08 mg/kg/day (21 day exposure)</p>	<p>Hamada N. (1992b)</p>
<p>Inhalation</p>	<p>Not established - study not scientifically justified</p>		

Only the relevant or key studies have been included here. For the rest of studies, please see the CAR.

4.7.1 Non-human information

4.7.1.1 Repeated dose toxicity: oral

An study intended for evaluating the subchronic oral toxicity for a period exceeding 90 days, were performed dosing Chlorophacinone, dissolved in corn oil, administered by gavage (oral intubation) to rats, 7 days/week at dosages of 0, 5, 10, 20, 40, 80, 160 µg/kg bw per day for a period ranging from 11 to 16 weeks. The study was conducted according to EC Method B.27 guidelines with some deficiencies: limited microscopic examination, clinical signs were not reported for each dose group. The low dose group was terminated after 11 weeks (77 days) (justified by Authors as due to the complete absence of any toxicological effects at this dose). Author and Applicant have considered that the extent of examination is sufficient to characterize the dose-response pattern and that these deficiencies do not impact the NOAEL determination or the study reliability. A main deficiency for a definitive adoption of NOAEL/LOAEL is that coagulation activity was not monitored at the lowest dose of 5 µg/kg bw/day, just the dose proposed for NOAEL. It is justified but in any case some uncertainty is maintained. The study is accepted BUT with the commented uncertainty.

This is a critical study as it is the only subchronic study and no chronic study is available. Therefore, it is analyzed in detail as follows:

Mortality

No mortality was noted at 5 µg/kg over the 11 weeks of study. One male and one female of 10 µg/kg died but was interpreted as due to intubation error and not considered for evaluation.

Mortality was noted in all dosage groups above 10 µg/kg. The frequency of mortality as well the survival time of animals was related to the administered dose.

Males were more affected than females:

- At 20 µg/kg 4 out of 10 males died during days 105-111 and no female died.
- At 40 µg/kg all the males died within 82 days (range 29-82 days), compared to 4 out of 10 females that died during days 69-111.
- All animals died in the 80 µg/kg groups during 7-16 days and in the 160 µg/kg group during 5-8 day, and with no clear difference between sexes.

Macroscopic examination

Group dosed at 5 µg/kg/day showed no hemorrhagic lesions. Thymusa haemorrhages were observed in some 10% animals dosed at 10 µg/kg/day and in most animals (≥90%) of groups at 20, 40 and 160 µg/kg. and frequent haemorrhages were also noted in haemothorax, haemoperitoneum, and haemorrhages at the stomach, the digestive tract, and the hypophysis, and at 20 µg/kg. At 40 and 80 µg/kg/day also haemorrhages were noted in lungs, testicles, prostate and other.

Clinical signs

The dominant clinical signs that were responsible for death of animals were related to the anticoagulant activity of chlorophacinone. Animals appeared weakened with decreased mobility and haemorrhages both externally and internally.

Clinical chemistry

Biochemical parameters were generally unaffected by chlorophacinone at the lowest levels examined (the level without mortality). However, at 10 and 20 µg/kg/day, increases in urea and

creatinine levels, bilirubin, cholesterol, triglycerides, and ASAT and ALAT, were suggestive of hepatic and renal disorders.

Haematology-Coagulation

With the exception of the coagulation time, haematological parameters were similar to controls. The only parameter having toxicological relevance in both sexes was an increase in coagulation (quick) time, which was notably pronounced in groups 20 and 40 µg/kg/day and were minimal in group 10 µg/kg but statistically significant. The other few variations, which were not dose related, were considered to be of no toxicological significance.

Surprisingly, the animals of the lowest dosage group (5 µg/kg) were not examined for coagulation time and was not continued for the entire 16 weeks of study as they were stopped at week 11 (day 77). It was justified because the absence of any sign of toxicity. So a full evaluation cannot be made of this dosage group.

NOAEL/LOAEL deduced from the subchronic study in rats

The authors of the study and the manufacturer deduced that the NOAEL for this study is 5 µg/kg/day on the basis of no clinical, pathological and histopathological effect observed during the 77 days of the study at this dose (although no haematological studies on coagulation time were performed at this dose level. The next dose level of 10 µg/kg/day might be considered at the LOAEL at which no death are observed but caused minimal but statistically significant increase in coagulation (quick) time and alterations of some biochemical parameters indicator of hepatic and renal alterations.

As the dose of 10 µg/kg/day only caused minimal increase in coagulation time, in the complete absence of clinical, pathological alterations the dose tested of 5 µg/kg/day, it is reasonable to accept this dose as NOAEL. However the lack of monitoring coagulation parameters and the shorter time of dosing and observation at this dose, involves some uncertainty in the conclusion of the NOAEL. Consequently this uncertainty will have to be considered for risk assessment.

Summary conclusion of subchronic oral study in rats

- High mortality is observed at dose 20 µg/kg/d or higher for males and 40 µg/kg/d or higher for females. Males were more sensitive to the lethal effects of Chlorophacinone than females. (At 20 µg/kg/day 4 males died. At 40 µg/kg/day all the males died within 82 days (range 29-82 days), compared to 4 out of 10 females that died during days 69-111)
- The dominant clinical signs were related to the anticoagulant activity of Chlorophacinone and were responsible for death of animals. Macroscopic examination revealed extensive haemorrhagic lesions in all dosage above 20 µg/kg/day, with a few haemorrhages in the 10 µg/kg/d group and none noted at 5 µg/kg/d. Gross and microscopic examinations of tissues/organs were consistent with the visual observation of hemorrhagic activity and with the known anticoagulant properties of Chlorophacinone.
- Coagulation (quick) time which were notably pronounced in groups 20 and 40 µg/kg and were minimal in group 10 µg/kg/day but significantly different from controls.
- A **LOAEL of 10µg/kg/day** is established on the basis of 16 weeks dosing period with minimal increase but statistically significant in coagulation time and other biochemical parameters alteration which are suggestive of hepatic and renal disorders
- It is concluded that for subchronic oral toxicity **NOAEL value of 5 µg/kg bw/day** can be established based on results from 11 weeks (77 days) administration. An uncertainty is maintained on this conclusion as no coagulation time were measured at this dose and this group were terminated before the 90 days, justified by the complete absence of toxicological effects.

- The uncertainty in NOAEL/LOAEL will be addressed for risk characterization assuming an additional assessment factor of 3.

4.7.1.2 Repeated dose toxicity: inhalation

-

4.7.1.3 Repeated dose toxicity: dermal

There are not specific acceptable data available for repeated dose dermal exposure with the active substance.

In the range finding study, Chlorophacinone (100% purity) was topically applied for 6-hour for 5 days/week, for 3 weeks at 1.0, 0.3, 0.1, 0.03, 0.01 and 0.003 mg/kg bw/day in rabbits (2 animal (1 male, 1 female)

Mortalities were observed from 0.1 mg/kg/d (1 females) and both males and females at the two highest doses (1 and 0.3 mg/kg/day) died during the dosing period. All the animals that died during the study either lost weight or had only a slight gain in weight. The necropsy revealed blood in the thoracic cavity, subcutaneously in the neck region, liver, stomach, bladder, brain, and the small intestine. No unusual lesions were noted in any of the surviving animals.

A full study was carried out with the formulation tracking power containing 0.2 % of active substance. It was applied to New Zealand White rabbits dermally 5 days a week for 3 weeks to 10 animals (5 males and 5 females) per group. The dose levels of active substance were 0.08, 0.40 and 2 mg/kg/day.

At 2.00 mg/kg/day dose 4 males died on day 14, 15, 16, 18, and one female on day 21. Evidence of haemorrhage and moderate to moderately severe centrilobular liver necrosis was seen at the necropsy of each of the animals. Cage side/clinical compound-related signs included anorexia, few faeces, pale eyes, hypoactivity, and dyspnea.

A dose of 0.4 mg chlorophacinone/kg/day did not produce any clinical/clinical compound-related signs, mortality, body weight and food consumption changes, or changes in gross pathology or histopathology. All animals lost weight during first week but had recovered it by the second week.

Compound related increase in prothrombin values were observed in the males and females of the 0.4 and 2 mg/kg/day dose groups and the low dose (0.08 mg/kg/day) was not causing effect in both males and females.

The study allows getting NOAEL by dermal exposure as 0.08 mg/kg/d in rabbit dosed as tracking power formulation being the most sensitive observation the alteration of prothrombin times which was observed at 0.4 and 2 mg/kg/day.

The mid dose of 0.4 mg/kg bw did not produce compound related clinical signs mortality nor pathological or histopathological changes. The highest dose of 2 mg/kg/day caused high mortality (4/5 males and 1/5 females).

The conclusion has not general value but only for the formulation used as tracking power. The range finding study using the active substance in a limited number of animals (6 doses, 2 animal/group) suggested that the critical dose might be in the range of 0.03 to 0.1 mg/kg. Although that study cannot be used for deducing NOAEL for risk assessment it is useful to confirm that the study with the formulation could be acceptable.

No data of dermal absorption are available in rabbit skin, so the dermal repeated study in rabbit cannot be directly used for estimating the no-effect systemic dose, and consequently no direct use can be done for risk characterization by comparison with systemic dose estimated for human exposure.

4.7.1.4 Repeated dose toxicity: other routes

4.7.1.5 Human information

4.7.1.6 Other relevant information

4.7.1.7 Summary and discussion of repeated dose toxicity

The toxicity response of Chlorophacinone shows very “drastic” dose-effect relationship (high slope in dose-response curve). The toxic doses are lethal showing lethality after some time of repeated dosing. In most studies, the next dose higher than NOAEL is showing high lethality due to haemorrhage, although in some case it is possible to observe a dose with low lethality with altered coagulant parameter (as prothrombin time). The anticoagulant property of Chlorophacinone is responsible of the toxicity and no other effects are significant in comparison with the so relevant anticoagulant property. At higher doses, lethality occurs at shorter time whereas at lower doses lethality only occurs after longer time of repeated dosing but in any case after an accumulative time of repetitive dosing, haemorrhage is causing lethality.

Repeated dermal toxicity (21 days study): There are not specific acceptable data available for repeated dose dermal exposure with the active substance. There is a range finding study which is useful to confirm the value of the available study with the formulation tracking power. A full study was performed with the formulation tracking power containing 0.2 % of active substance in New Zealand White rabbits. The study allows obtaining NOAEL by dermal exposure as 0.08 mg/kg/d in rabbit dosed as tracking power formulation being the most sensitive observation the alteration of prothrombin times which was observed at 0.4 and 2 mg/kg/day. No data of dermal absorption are available in rabbit skin, so the dermal repeated study in rabbit cannot be directly used for estimating the no-effect systemic dose, and consequently no direct use can be done for risk characterization by comparison with systemic dose estimated for human exposure.

Subchronic oral toxicity in rats: A study intended for evaluating the subchronic oral toxicity for a period exceeding 90 days, were performed dosing Chlorophacinone, dissolved in corn oil, administered by gavage (oral intubation) to rats, 7 days/week at dosages of 0, 5, 10, 20, 40, 80, 160 µg/kg bw per day for a period ranging from 11 to 16 weeks. The study was conducted according to EC Method B.27 guidelines with some deficiencies: limited microscopic examination, clinical signs were not reported for each dose group. The low dose group was terminated after 11 weeks (77 days) (justified by Authors as due to the complete absence of any toxicological effects at this dose). An uncertainty for a definitive adoption of NOAEL/LOAEL is that coagulation activity was not monitored at the lowest dose of 5 µg/kg bw/day, just the dose that later is proposed for NOAEL. It is technically and operationally justified but in any case some uncertainty is maintained. The study is accepted but with the commented uncertainty.

No mortality was noted at 5 µg/kg over the 11 weeks of study. One male and one female of 10 µg/kg died but was interpreted as due to intubation error and not considered for evaluation. Mortality was noted in all dosage groups above 10 µg/kg. High mortality is observed at dose 20 µg/kg/d or higher for males and 40 µg/kg/d or higher for females. The dominant clinical signs were

related to the anticoagulant activity of Chlorophacinone and were responsible for death of animals. Alteration in coagulation parameters (Quick test time) were notably pronounced in groups 20 and 40 µg/kg and were minimal in group 10 µg/kg/day but significantly different from controls. A LOAEL of 10µg/kg/day is established on the basis of 16 weeks dosing period with minimal increase but statistically significant in coagulation time and other biochemical parameters alteration which are suggestive of hepatic and renal disorders. It is concluded that for subchronic oral toxicity NOAEL value of 5 µg/kg bw/day can be established based on results from 11 weeks (77 days) administration. An uncertainty is maintained on this conclusion as no coagulation time was measured at this dose and this group was terminated before the 90 days. The uncertainty in NOAEL/LOAEL is considered for risk characterization.

A *repeat dose inhalation study* is not presented. Applicant argue that considering the acute inhalation toxicity and the anticoagulant properties, an inhalation repeated dose study as it will result in death by induction of a haemorrhagic syndrome including at low dose. Therefore if these arguments for waiving of repeated inhalation study is accepted, it involves accepting that is actually "very toxic by inhalation" and R26 should be applied.

4.7.1.8 Summary and discussion of repeated dose toxicity findings relevant for classification according to DSD

4.7.1.9 Comparison with criteria of repeated dose toxicity findings relevant for classification according to DSD

4.7.1.10 Conclusions on classification and labelling of repeated dose toxicity findings relevant for classification according to DSD

Classification with **T; R/48/23/24/25** is warranted based on:

- the repeated dermal toxicity and
- subchronic oral toxicity
- data plus extrapolation from the acute data for inhalation route of exposure

4.8 Specific target organ toxicity (CLP Regulation) – repeated exposure (STOT RE)

4.8.1 Summary and discussion of repeated dose toxicity findings relevant for classification as STOT RE according to CLP Regulation

Category 1 - STOT RE 1

H372: Causes damage to organs (blood coagulation system, liver, kidney) through prolonged or repeated exposure

4.8.2 Comparison with criteria of repeated dose toxicity findings relevant for classification as STOT RE

CLP Regulation:

Category 1 - STOT RE 1

H372: Causes damage to organs (blood coagulation system, liver, kidney) through prolonged or repeated exposure

DSD:

R48/23/24/25: Toxic: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed.

4.8.3 Conclusions on classification and labelling of repeated dose toxicity findings relevant for classification as STOT RE

Classification: Category 1 - STOT RE 1

Labelling:

- a. Pictogram: GHS08
- b. Signal Word: Danger
- c. Hazard Statement:

H372: Causes damage to organs (blood coagulation system, liver, kidney) through prolonged or repeated exposure

No route is specified as it is concluded that all routes (oral, dermal and inhalation) may cause repeated dose toxicity fulfilling the criteria for classification.

4.9 Germ cell mutagenicity (Mutagenicity)

In vitro:

CLH REPORT FOR [CHLOROPHACINONE]

Test system Method Guideline	Organism/ strain(s)	Concentrations tested	Result		Remarks	Reference
			+ S9	- S9		
			+/-/±	+/-/±		
Bacterial reverse mutation test EPA 84-2a	Salmonella typhimurium strains: TA 98, TA 100, TA 1535, TA 1537, TA 1538	2, 10, 50, 250 µg per plate	- ve	- ve	<u>Chlorophacinone did not induce a mutagenic effect.</u> Cytotoxic at 250 µg without S9 for TA 1535; 250 µg with or without S9 for TA 1537, TA 1538, TA 100; 50 and 250 µg without S9 for TA 98 and 50 µg without S9 for TA 1538	Betbeder-Matibet A., (1981)
Bacterial reverse mutation test EPA 84-2	Salmonella typhimurium strains: TA 98, TA 100, TA 1535, TA 1537 Escherichia coli strain: WP2uvrA	Salmonella typhimurium strains: Without S9 mix: 100, 50, 10, 5, 1, and 0.5 µg per plate. With S9 mix: 500, 100, 50, 10, 5, 1 µg per plate (TA 98 an additional dose level of 0.5 µg per plate) Escherichia coli: Without S9 mix: 5000, 1000, 200, 50, 10, and 5 µg per plate. With S9 mix: 5000, 1000, 500, 100, 50, 10 µg per plate.	- ve	- ve	Chlorophacinone did not cause a positive increase in the number of revertants per plate with any of the tested strains in the presence or absence of activation.. <u>Chlorophacinone considered negative for mutagenicity.</u> Cytotoxicity seen in range finding study. Strain TA 100 showed cytotoxicity at concentrations of 100 µg/plate (S9+) and 33.3 µg/plate (S9-). WP2uvrA showed cytotoxicity at 100 µg/plate (S9-). No cytotoxicity with WP2uvrA was seen up to the highest level tested (3300 µg/plate)..	Lawlor T.E., (1994)
Mammalian chromosome aberration test EPA 84-2	Human lymphocytes	6.25, 12.5, 25, 50 µg/ml	- ve	- ve	Test material was considered to be non-genotoxic with or without metabolic activation Severe cytotoxicity was seen at the highest concentration.	Stankowski L.F. (1995)
Mammalian cell gene mutation test EPA 84-2	Chinese Hamster Ovary (CHO)	5, 10, 50, 100, 200 µg/ml	- ve	- ve	<u>Chlorophacinone did not induce mutagenic effects in CHO cells (HGPRT) locus with or without metabolic activation.</u> Cytogenicity observed at 200 µg/ml in both the presence and the absence of S9.	Weill N., (1990)

In vivo:

Type of test Method/ Guideline	Species Strain Sex no/group	Frequency of application	Sampling times	Dose levels	Results	Remarks	Reference
Bone marrow mutagenicity EPA 84-2	Mouse CD1 (ICR) 5 male 5 female Additionally, 5 male and 5 female in mid dose group, 15 male and 15 female in highest dose	3 days consecutively	24 hours after the last dose	3.75, 7.5 and 15 mg/kg bw	Test material induced no significant increase in micronucleated PCEs over the levels observed in vehicle controls for males and females. There were deaths 72 hours after first dosing at 15 mg/kg	Chlorophacinone is considered negative in the mouse bone marrow micronucleus test, even at near-lethal levels.	Murli H., (1994)

4.9.1 Non-human information

4.9.1.1 In vitro data

Results for *in vitro* bacterial gene mutation and *in vitro* mammalian cell gene mutation **tests were negative**. The mouse micronucleus test was also negative. The Technical Notes for Guidance state that if these studies are negative then further testing is normally only required if there are metabolites of concern formed in mammals.

The studies summarized in point 4.1 indicates that faecal elimination (the only significant route of elimination) shows unchanged Chlorophacinone and two hydroxylated metabolites to account for at least 80% of radioactivity. The hydroxylated metabolites can be assumed to have similar toxicity to the parent material, as they closely resemble the parent material. One other metabolite (unidentified) was present at 8.1% of radioactivity, and other minor metabolites represented 3.4% of radioactivity. Given that none of these metabolites are likely to be more toxic than the active substance (it is reasonable to assume that in research to find suitable candidate molecules for rodenticides, the industry would have chosen the most toxic substances for the active substance), further genotoxicity testing of metabolites is not absolutely required.

However, there are no evidences in the data summarized in the report of chlorophacinone demonstrating if metabolites are or not less toxic than the parent compounds. Therefore, some uncertainty remains with the evaluation of the metabolites.

4.9.1.2 In vivo data

The study *in vivo* bone marrow and *in vitro* tests are negative.

4.9.2 Human information

4.9.3 Other relevant information

Given these study results and the no evidence of any metabolites of concern in mammals, further genotoxicity testing does not seem to be required.

4.9.4 Summary and discussion of mutagenicity

Chlorophacinone, does not fulfill the EU criteria for classification as a mutagenic substance.

4.9.5 Comparison with criteria

4.9.6 Conclusions on classification and labelling

Chlorophacinone, does not fulfill the EU criteria for classification as a mutagenic substance.

4.10 Carcinogenicity

Table 19: Summary table of relevant carcinogenicity studies

Method	Results	Remarks	Reference
	<p><u>Species/type of tumors</u>: The closely related molecule warfarin is not carcinogenic to humans. Study on chlorophacinone is not available. Applicant argument for non submission of data was accepted.</p> <p>Lowest dose with tumors: Not appropriate</p>		

4.10.1 Non-human information

Carcinogenicity and long-term toxicity studies have not been performed.

Chlorophacinone is structurally and functionally similar to the molecule warfarin. The long history of therapeutic use of warfarin gives evidences that warfarin is not carcinogen to human. The repeated doses studies showed no indications of either hyperplasia or hypertrophy at near lethal levels of administration. Chlorophacinone have been proved that is not mutagenic.

4.10.1.1 Carcinogenicity: oral

4.10.1.2 Carcinogenicity: inhalation

4.10.1.3 Carcinogenicity: dermal

4.10.2 Human information

4.10.3 Other relevant information

4.10.4 Summary and discussion of carcinogenicity

Study not required. Long term use of the structurally similar active substance warfarin in humans has shown. Based on the available data, no classification for carcinogenicity for Chlorophacinone is proposed.

4.10.5 Comparison with criteria

4.10.6 Conclusions on classification and labelling

Based on the available data, no classification for carcinogenicity for Chlorophacinone is proposed.

4.11 Toxicity for reproduction

Table 20: Summary table of relevant reproductive toxicity studies

Method	Results	Remarks	Reference
Species/ <u>Reproduction target</u> / critical effect:	The closely related molecule warfarin shows no adverse effects on human fertility. Study on chlorophacinone is not available. Applicant argument for non submission of data was accepted.	<u>Lowest relevant reproductive NOAEL / LOAEL</u> : Not appropriate	
Species/ <u>Developmental target</u> / critical effect (EPA 83-3)	<p><u>Rat</u></p> <p>High maternal toxicity (18 of 25) at the highest dose: (72% at 100 µg/kg bw) No mortalities at other doses. Pregnancy rate was high and equivalent across groups. Signs included external bleeding; pale eyes, ears, paws and tail; bleeding from vagina; prone position; laboured, slow or shallow breathing; chromodacryorrhoe and pilo-erection. They exhibited the following signs at necropsy: blood in vagina and amniotic sacs, blood mixed with ingesta in gastro-intestinal tract, pale organs including ovaries, spleen, kidneys, liver, adrenals, lungs, and multiple red foci on lungs. All signs of maternal toxicity seems to be related with the mode of action as antiVit-K anticoagulant.</p> <p>No indication of developmental toxicity (embryotoxicity /teratogenicity) including in foetus of dams at the higher dose.<u>Rabbit</u></p> <p>High maternal lethality 81% (13/16) and 100% (16/16) at 25 and 75 µg/kg bw. Pregnancy rate was high and equivalent across groups and there were no treatment-related effects on any gestational parameters</p> <p>All other females at lower doses survived and were pregnant. All pregnant does had one or more live foetuses at scheduled sacrifice. Clinical observation included: external bleeding around mouth, ears, and the urogenital system, pale eyes, ears, and lips/gums, lethargy, and blood in pan beneath cage. Signs at necropsy included: blood in neck and over thoracic cavity, blood in vagina, uterus and amniotic sacs, blood mixed with ingesta in gastro-intestinal tract, pale organs including ovaries, spleen, kidneys, liver, and multiple red foci on intestines, appendix and lungs. All sign of maternal toxicity seems to be related with the mode of action as antiVit-K anticoagulant.</p> <p>No indication of developmental toxicity (embryotoxicity /teratogenicity) including in foetus of dams at the higher dose.</p>	<p><u>NOAEL for maternal toxicity</u> of 50 µg/kg bw/day was adopted on the basis of mortality at higher dose (LOAEL 100 µg/kg bw/day)</p> <p><u>NOAEL for developmental toxicity</u> of 100 µg/kg bw/day</p> <p>Number of animals/Sex/Dose:</p> <ul style="list-style-type: none"> • Rat VAF CD Sprague-Dawley Female 25 per group • 0, 12.5, 25, 50, 100 µg/kg bw per day <p><u>NOAEL for maternal toxicity</u> of 50 µg/kg bw/day was adopted on the basis of mortality</p> <p><u>NOAEL for developmental toxicity</u> of 25 µg/kg bw/day</p> <p>Number of animals/Sex/Dose:</p> <ul style="list-style-type: none"> • Rabbit New Zealand White Female 16 per group • 0, 5, 10, 25, 75 µg/kg bw per day 	<p>Tyl R.W., Marr M.C., Myers C.B., (1994a)</p> <p>Tyl R.W., Marr M.C., Myers C.B., (1994b)</p>

This MS is not proposing classification of chlorophacinone for reproduction (neither fertility nor development). Therefore, in principle, detail information of studies about reproduction were not required in this Annex XV. However it was considered necessary to include and discuss the available information about teratogenicity for chlorophacinone and compare with existing information on warfarin, due to the previous history of the proposal for R61 for all anti-vitamin K rodenticides by read across from the human embryotoxicity of warfarin.

4.11.1 Effects on fertility

4.11.1.1 Non-human information

4.11.1.2 Human information

4.11.2 Developmental toxicity

Teratogenicity studies show no teratogenic effect. Embryogenesis period not tested. Chlorophacinone administered orally during major organogenesis in rats and in rabbits gave no indication of developmental toxicity at all evaluated tested doses, including the highest doses which had enough surviving pregnant animals for evaluation of embryotoxicity and teratogenicity (100 µg/kg/day in rats and 25 µg/kg/day).

Study in Rats

- Maternal effects:

No alterations were observed in pregnancy rate (96-100%) in all groups. No dams aborted, delivered early, or were removed from the study. Mortality: 18/25 at 100 µg/kg/day died or were sacrificed moribund on gd 12(1), 13 (8), 14 (8), 16 (1).

Clinical signs were limited to animals dosed at 100µg/kg/day. Signs included external bleeding; pale eyes, ears, paws and tail; bleeding from vagina; prone position; laboured, slow or shallow breathing; chromodacryorrhoe and pilo-erection. They exhibited the following signs at necropsy: blood in vagina and amniotic sacs, blood mixed with ingesta in gastro-intestinal tract, pale organs including ovaries, spleen, kidneys, liver, adrenals, lungs, and multiple red foci on lungs. All other females survived and were pregnant.

There were no apparent treatment-related clinical signs of toxicity at the other doses. At the scheduled necropsy, there were no treatment-related findings.

All pregnant dams had one or more live foetuses at scheduled sacrifice except for one at 50 µg/kg/day with a fully resorbed litter. Maternal body weights and weight gains were equivalent across all groups for all time points or intervals. Maternal gravid uterine weight and absolute and relative liver weights were statistically and biologically equivalent across all groups.

Maternal food consumption exhibited no treatment-related changes.

- Developmental effects:

Chlorophacinone administered orally during major organogenesis (gestational days 6 through 15) gave no indication of developmental toxicity including teratogenicity at the highest doses of 100 µg/kg/day which are causing high maternal mortality (18 of 25, 72%) with enough surviving dams (7 of 25, 28%) for evaluation of embryotoxicity and teratogenicity.

For maternal toxicity a NOAEL of 50 µg/kg bw/day was adopted on the basis of mortality at higher dose. Clinical signs of toxicity and necropsy pathology demonstrated that mortalities were due to internal haemorrhage related with the anticoagulant properties of the substance.

Study in Rabbits

Chlorophacinone was tested to produce maternal and developmental toxicity (including teratogenicity) in rabbits by gavage once daily, on gestational days 7 through 19 at doses 0, 5, 10, 25, 75µg/kg/day.

The numbers of litters and foetuses evaluated were 16 (135), 14 (115), 16 (125), 2 (16) at 0, 5, 10, 25µg/kg/day; no does survived to scheduled sacrifice at 75 µg/kg/day; high mortality occurred at 25µg/kg/day (13 of 16) but at least the foetuses of 2 does were possible to evaluate for embryotoxicity and teratogenicity.

- Maternal toxicity:

Pregnancy rate was high and equivalent across groups (93.3-100.0%) with no dose related changes.

Mortality, clinical and pathology: At the highest dose (75 µg/kg/day), all 16 does died or were sacrificed moribund (100 %). At 25µg/kg/day, 13 out of 16 does died (81%). All other females at lower doses survived and were pregnant. All pregnant does had one or more live foetuses at scheduled sacrifice. Clinical observation included: external bleeding around mouth, ears, and the urogenital system, pale eyes, ears, and lips/gums, lethargy, and blood in pan beneath cage. Signs at necropsy included: blood in neck and over thoracic cavity, blood in vagina, uterus and amniotic sacs, blood mixed with ingesta in gastro-intestinal tract, pale organs including ovaries, spleen, kidneys, liver, and multiple red foci on intestines, appendix and lungs.

Clinical and pathology of surviving does. Treatment-related clinical observations were limited to does at 75 and 25 µg/kg/day prior to death. There were no treatment-related clinical signs of toxicity at 10 and 5µg/kg/day. At scheduled necropsy, there were no treatment-related findings in surviving does.

Maternal body weights and weight gains were equivalent across all groups for all timepoints or intervals with a significant dose-related downward trend, with no significant pairwise comparisons to the control group.

Organ weight. Maternal gravid uterine weights and liver weights were statistically and biologically equivalent across all groups.

Maternal food consumption exhibited no treatment-related changes, except for a significant reduction at 75.0 µg/kg/day, prior to death.

NOAEL for maternal toxicity: A value of 50 µg/kg bw/day was adopted on the basis of mortality at higher dose. Clinical signs of toxicity and necropsy pathology demonstrated that mortalities were due to internal haemorrhage related with the anticoagulant properties of the substance.

- Developmental effects:

Chlorophacinone administered orally in rabbits during major organogenesis (gestational days 7 through 19) gave no indication of developmental toxicity including teratogenicity at the highest evaluated doses (25 µg/kg/day) which are causing high maternal mortality (13 of 16, 81%) with surviving does (3 of 16) for evaluation of embryotoxicity and teratogenicity.

There were no significant effects of treatment on any gestational parameters, including number of ovarian corpora lutea, total number of uterine implantation sites, pre- or post-implantation losses, number of live foetuses per litter, sex ratio or foetal body weight per litter, when calculated as all foetuses, or males or females. There were no treatment related changes in the incidence of individual or pooled external, visceral, skeletal or total malformations or variations.

There were no foetal external variations observed. Foetal visceral and skeletal variations were equally distributed across groups

No developmental effects were noted at any dose. So, NOAEL for developmental toxicity was considered the highest tested dose with about 20 % does surviving. At 75 µg/kg bw/day, 100 % mortality was observed, and at 25 µg/kg bw/day, a high mortality (13 of 16) was also observed but no significant effect were detected in the foetus of the surviving dams.

So it is concluded that no developmental effect was observed including at the highest dose with surviving does. Strictly, NOAEL for developmental toxicity cannot be established. For a practical point of view for later assessments, a NOAEL for developmental toxicity of 25 µg/kg bw/day is adopted.

4.11.2.1 Non-human information

4.11.2.2 Human information

4.11.3 Other relevant information

4.11.4 Summary and discussion of reproductive toxicity

For maternal toxicity a NOAEL of 10 µg/kg bw/day on the basis of mortality in rabbit was adopted. Clinical of toxicity and necropsy pathology demonstrated that mortality in rats and rabbits was due to internal haemorrhage caused by the anticoagulant properties of the substance. Treatment-related clinical observations were limited to does causing mortality prior to death. There were no treatment-related clinical signs of toxicity at lower doses. At scheduled necropsy, there were no treatment-related findings in surviving pregnant animals.

No developmental effects were noted at any tested evaluated dose in two studies in rats and rabbits. In the first study in rat, the highest dose of 100 µg/kg bw per day caused 72% mortality (18 out of 25) without any significant observed effect in foetus of the surviving dams. In the second study in rabbit , 100 % mortality was observed at 75 µg/kg bw/day and at 25 µg/kg bw/day, a high mortality (13 of 16) was also observed but no significant effect were detected in the foetus of the surviving does.

So it is concluded that no developmental effect was observed at the highest possible dose with surviving pregnant animals in experimental guideline tests. Strictly NOAEL for developmental toxicity cannot be established. For a practical point of view for further risk characterization, a NOAEL for developmental toxicity of 25 µg/kg bw/day is adopted on the basis of no embryotoxic and teratogenic effect at the highest evaluated dose in the teratogenicity study in rabbit.

It is a matter of discussion if the standard teratogenicity test is appropriate for anticoagulant rodenticides, in particular when data is intended to be used to deduce no classification for reproduction-development as the embryogenesis period is not tested and no study of two generation reproduction may be tested. Classification of all anticoagulant rodenticides from read across from warfarin has been suggested on the basic of the teratogenic/embryotoxicity properties of warfarin in human pregnancy, when administered as a pharmaceutical. Non-guideline non-GLP studies with warfarin in animals have shown equivocal effects, this circumstance, together with the absence of adverse findings in the rat and rabbit teratogenicity studies with other AVKs lead the TC C&L to conclude that a study according to the OECD 414 guideline was not capable of detecting effects with AVKs, concluding that it was appropriate to read across from the known human effects of

warfarin to other AVKs, and classify all of them as Cat 1 or Cat 2 R61. However, the new OECD 414 study available for warfarin sodium affects the reasons for classification of chlorophacinone.

The study carried out with warfarin sodium shows a definitive increase in incidence of subcutaneous and internal foetal haemorrhage (not seen in studies with chlorophacinone), foetal ocular effects and some indications of reduced ossification in skull bone at higher dose levels (see point 6). This study is relevant but not essential for the classification of warfarin, because human data supporting classification are available. However, it is relevant for chlorophacinone as it demonstrates that the test is able to show the possible teratogenicity of AVK. On the other hand, the different results in the test between warfarin and chlorophacinone with regard to foetal haemorrhages could indicate a difference in foetal availability. Therefore, some differences in relation to the developmental effects may be expected between warfarin and chlorophacinone.

The adverse finding detected in a standard OECD 414 study for warfarin sodium, would validate the negative findings in a similar study with chlorophacinone. Therefore, the phrase R61 is not warranted. Nevertheless, taking into account the comparable chemical structure and toxicological activity of warfarin and chlorophacinone, it may be possible to think that chlorophacinone could induce the effects observed with warfarin if chlorophacinone is present at or above a certain level in the foetus. However, this would be unlikely because the highest concentration recorded in the test was 100 µg/kg bw per day and this caused 72% mortality without any significant observed effects in foetus on the surviving dams. Similar situation is confirmed in rabbit study with 81 and 100 % mortality at 25 and 75 µg/kg bw per day and clinical signs of external and internal bleeding related with its mode of action as anti-VitK anticoagulant effects.

Chlorophacinone causes in adults similar toxic effects with haemorrhages by the same mode of action (antivit K) as other related rodenticides including warfarin and similar maternal toxicity in the teratogenicity test. However at doses causing high maternal toxicity and lethality no haemorrhages and no cataracts are observed in foetus in contrast with the effects by warfarin

The different results in the test between warfarin and chlorophacinone with regard to foetal haemorrhages suggest a clear difference in foetal availability. Therefore, differences in relation to the developmental effects may be expected.

The main argument for classifying all AVK rodenticides as warfarin is based on the common mode of action.

We agree that chlorophacinone has the same mode of action but just this justifies that it cannot be classified because with this mode of action it cannot cause effect at non-lethal dose. No anticoagulant level of the compound seems to be available in the foetus at doses that are causing very severe and lethal effects in the mother through the same mode of action. Therefore the prediction is that embryotoxic developmental effects are not possible to be caused by chlorophacinone at any non-lethal maternal dose.

Therefore classification as for warfarin is not possible.

The only uncertainty is due to the lack of studies comparing levels of the substance in the foetus with the mother blood. No different clotting mechanism is expected in the foetus. Therefore, it seems obvious that availability is much lower in the foetus as no bleeding is observed at doses causing severe maternal haemorrhages. Moreover there are no reasons to believe that the availability of chlorophacinone might be higher to human foetus than in rats or rabbits. Therefore, that uncertainty is doubtful to justify classification including for the lowest level of Cat 2, and clearly not supporting Cat 1B or 1A

4.11.5 Comparison with criteria

4.11.6 Conclusions on classification and labelling

Based on the available data, **no classification** for fertility neither for developmental toxicity for Chlorophacinone seems to be warranted.

4.12 Other effects

4.12.1 Non-human information

4.12.1.1 Neurotoxicity

The closely-related active substance Difethialone was investigated, in various screening tests (Refer to the study summaries (Doc. IIIA 6.9-01) in the draft CA- report on Chlorophacinone), for potential pharmacological activity other than its known anticoagulant properties. Specifically, the following endpoints were investigated: antianginal activity *in vivo* or *in vitro*; antihypertensive activity; sedative activity; anticonvulsant activity; antidepressant activity; antispasmodic activity in a variety of *in vitro* tests; analgesic, anti-inflammatory or gastric antacid activity. The absence of sedative activity, anticonvulsant activity, antidepressant activity and the absence of any clinical signs in rodent and dog toxicity tests with Chlorophacinone also support the conclusion that there are not evidences that Chlorophacinone could show specific neurotoxic effects.

4.12.1.2 Immunotoxicity

4.12.1.3 Specific investigations: other studies

4.12.1.4 Human information

There are no published data on specific cases of Chlorophacinone intoxication, and no case reports from the manufacturer concerning adverse effects in users applying the products. The closely-related active substance warfarin has been in use for over forty years as an anticoagulant drug in human medicine. Its use is described in more detail in 3, but in summary it has been used in millions of patients with clotting disorders, heart disease, atrial valve replacement, and more recently, deep vein thrombosis. Use is life-long for most patients with heart disease, clotting disorders or valve replacement. There have been no reports of any increase in tumors incidence or of any adverse effects on human fertility. There have been no reports of neurotoxic or neurodegenerative disease, or neuromuscular disease associated with the use of warfarin. Use during pregnancy is contraindicated.

4.12.2 Summary and discussion

4.12.3 Comparison with criteria

4.12.4 Conclusions on classification and labelling

5 ENVIRONMENTAL HAZARD ASSESSMENT

A detailed summary of the available studies has been reviewed under the Biocidal Products Directive (98/8/EC), see Document IIA attached to the technical dossier. The key information pertinent to determining a classification position is presented below.

5.1 Degradation

Table 21: Summary of relevant information on degradation

Method	Results	Remarks	Reference
Hydrolysis OECD 111 EPA OPPTS 835.2100.	DT ₅₀ value equivalent to > 1 year (0.6 mg a.s/l; pH~4, 7 and 9) at temperatures up to 70°C		Adam, D., 2003,
Photolysis in water Commission directive 95/26/EC; Annex II: 2.9.2 and 7.2.1.2 Photochemical degradation OECD draft August 2000 and EPA OPPTS 835.2210	DT ₅₀ = 0.78 d (0.82 ug a.s/l; buffer pH 7; Photolysis rate constant (k _p ^c) = 0.88712; 25°C)	In aqueous solution (at 25°C), chlorophacinone is photolysed with a mean DT ₅₀ value of 0.62 days under artificial sunlight.	Diehl, M., (2004)
Photolysis in water OECD and EPA OPPTS 835.2210	DT ₅₀ = 0.45 d (0.82 ug a.s/l; pond water pH~8.4; Photolysis rate constant (k _p ^c) = 1.52564. 25 °C)		Diehl, M., (2004)
Photo-degradation on a soil surface US EPA Pesticide Assessment Guidelines, Subdivision N, Paragraph 161-3	Converted to a temperature of 12°C the DT ₅₀ and DT ₉₀ values for the photo-degradation of Buckeystown sandy clay loam soil are 11.1 and 86.8 days, respectively.		Spare, W., 1992
Transformation and fate in air Atmospheric Oxidation Program v1.90 (AOPWIN) using the Atkins method	In conclusion, significant amounts of chlorophacinone are not likely to volatilise or persist in air.		Curl, M.G., 2004
Biodegradation under aerobic conditions. Biodegradability (ready), manometric respirometry test (OECD 301 F)	chlorophacinone is not biodegradable under environmentally relevant conditions or expected to be biodegradable during sewage treatment processes		Peither, A., 2003
Biotic degradation in soil. Aerobic degradation in soil (initial study). US EPA Pesticide Assessment	In soil under dark aerobic conditions in the laboratory (12°C extrapolated from 25°C), chlorophacinone is degraded	2 soil types. Aerobic conditions	Spare, W., 1994

Guidelines, Subdivision N, Paragraph 162-1	steadily with an estimated DT ₅₀ value of 128 days. Degradation of chlorophacinone results predominantly in the formation of carbon dioxide (61.0% AR after <i>ca</i> 100 days) (mineralization). Metabolites (including o-phthalic acid and p-chlorophenyl phenyl acetic acid) do not exceed 10% AR at any sampling interval. Soil non-extractable residue (NER) comprises 9.0% AR after <i>ca</i> 100 days.		
Adsorption/desorption screening test US EPA Pesticide Assessment Guidelines, Subdivision N, Paragraph 163-1	Chlorophacinone is strongly adsorbed to soil. The amount of chlorophacinone adsorbed to soil was > 36.6 to > 85.2% during the adsorption phase. The Freundlich soil sorption coefficient normalised for organic carbon content (K _{oc}) was 15,600 to 136,000 ml/g. This result indicates chlorophacinone as 'non mobile' according to the SSLRC classification index. The Freundlich exponent (1/n) ranged from 1.145 to 1.231. In the case of chlorophacinone, adsorption to soil does not depend only on the organic carbon content.		Spare, W., 1993

5.1.1 Stability

A **HYDROLYSIS** study is available according to OECD 111 EPA OPPTS 835.2100. The abiotic degradation of chlorophacinone in the dark (i.e. hydrolysis) was investigated in aqueous solutions at three different pH values. Initially, a Pre-Test was performed at a concentration about 0.6 mg a.s/l for 5 days at 50°C in the dark using buffer solutions at pH~4, 7 and 9. Additionally, a Main Test was performed for pH~4 at 60 and 70°C. At temperatures of 60 and 70°C, insignificant degradation of chlorophacinone was observed at pH~4. The study was not conducted at temperatures of 60 and 70°C at pH values of 7 and 9 as insufficient degradation was observed at lower temperatures. The recovery of the applied radioactivity ranged from 93.9 to 104.6% throughout the investigation. The pH of the buffer solutions (citrate, phosphate and borate buffer 0.01M) was maintained throughout the duration of the study. Although some degradation of chlorophacinone was observed in buffer solutions at pH~4 at a temperature of 50°C, no significant degradation was observed at higher temperatures.

Chlorophacinone is stable to hydrolysis with an estimated half-life of > 1 year at all environmentally relevant pH values. No significant degradation products were formed. Although in the hydrolysis pre-test, conducted at 50°C, M2 appeared above 10% (30.9%) due to the results of

the test at 60 and 70°C, where all the metabolites were below 10%, M2 is considered of no relevance. Hydrolysis of chlorophacinone is not expected to be a significant process in the environment.

Chlorophacinone exhibited little hydrolytic degradation under sterile aqueous conditions (pH~4, 7 and 9) at temperatures up to 70°C. Chlorophacinone is considered stable to hydrolysis with a DT₅₀ value equivalent to >1 year at environmentally relevant temperatures therefore hydrolytic degradation is not expected to be a significant process in the environment. Reliability 1.

An **AQUEOUS PHOTOLYSIS** study under laboratory conditions was performed, according to OECD and EPA guidelines (Commission directive 95/26/EC; Annex II: 2.9.2 and 7.2.1.2 Photochemical degradation OECD draft August 2000 and EPA OPPTS 835.2210) (phototransformation in water study with ¹⁴C-chlorophacinone). The photolysis of chlorophacinone under artificial sunlight was rapid in both buffer solution and pond water, with 41.5 and 22.1% AR, respectively, remaining as chlorophacinone after 1 day. The rate of photolysis of chlorophacinone in aqueous solution was investigated under artificial sunlight, Hanau Suntest, in sterile pH~7 buffer and in sterile pond water, the latter with a pH of 8.4 post sterilisation, at 25.0±0.1°C. Test solutions were prepared and their duplicates, controls and dark control samples. The sterile solutions were continuously irradiated through their borosilicate lids, which absorb radiation < 290 nm, similar to the natural cut-off by ozone. Sterile, filtered, humidified air was drawn through the incubation vessels over the solutions at approximately 10 ml/minute. Any radioactive carbon dioxide or organic volatiles in the purged air was captured in traps of ethylenglycol followed by 2N NaOH, respectively.

The definitive phase of the study was conducted over 13 days. Sampling irradiated 0, 4 hours, 1, 3, 4, 7 and 13 d. Dark control 1, 3 and 13 days. At each sampling interval the level of radioactivity in solution (including a rinse of the test vessel with acetonitrile) was quantified by LSC and analysed directly by HPLC. Volatile traps were sampled and exchanged with fresh reagent at each sampling interval. Sunlight measurements and temperatures were recorded at each sampling interval. A preliminary test was performed as a range finding test. A chemical actinometer was not used for this study.

The best fit DT₅₀ value for the photolysis of chlorophacinone in sterile buffer solution (pH~7) was determined to be 0.78 days (DT₉₀=2.60 days; R²=0.99881) and in sterile pond water (pH~8.4) 0.45 days (DT₉₀=1.51 days; R²=0.99018). The buffer solution DT₅₀ (0.78 days) following continuous "Suntest" irradiation corresponded to 2.2 days natural summer sunlight at latitude 50°N and to 2.1 days at latitude 30-40°N, based on standard calculations. Concerning the pond water DT₅₀ (0.45 days) following continuous "Suntest" irradiation corresponded to 1.3 days natural summer sunlight at latitude 50°N and to 1.2 days at latitude 30-40°N, based on standard calculations. The photolysis of chlorophacinone, under artificial sunlight, gave a good correlation to pseudo first order kinetics (R² values were ≥ 0.99) rate constants (k_p^c) were 0.88712 and 1.52564 days⁻¹ for the buffer and pond water samples, respectively. The sunlight reaction quantum yield (ϕ_E^c) of the test substance was not determined. Photolysis of chlorophacinone in aqueous sterile buffer solution and sterile pond water led primarily to the formation of carbon dioxide, which reached levels of 85.8 and 69.1% AR, respectively after 13 days. Three unidentified photolysis products (M1, M2 and M3), separated by HPLC, were observed in the buffer solution and pond water samples reaching maximum levels of 23.4, 4.4 and 8.8% AR, respectively. Levels of each compound were declining at the final sampling interval (13 days). Levels of M2 and M3 were not significant (i.e. < 10% AR). In pond water, M1 reached a level of 23.4% AR after 4 days, declining thereafter to < 10% AR at 13 days; but since photolysis is a process which occurs mainly in the superficial layer of the water body this metabolite will not be further considered. Photolysis only happens between 10% and 50% (worst case) of the water body, the upper layer. The risk arising from M1 is considered covered by


the parent. The maximum occurrence is 23.4% in the fourth day. With this assumption if the chlorophacinone metabolised to M1, it would be necessary that the toxicity of the metabolite was between 8 (50% of the water body suffering photolysis) and 40 times (10% of the water body were photolysis was a relevant abiotic degradation process) more toxic than the active substance for the risk not to be covered. In buffer solution, M1 was a minor component observed at a maximum of 7.5% AR at day 4. The amount of applied radioactivity (AR) recovered from the buffer and pond water exposed samples ranged from 79.7 to 104.9% (overall average 90.9%) and 76.9 to 108.6% (overall average 88.9%), respectively. A satisfactory mass balance was achieved with low recoveries attributable to incomplete collection of carbon dioxide. The pH and sterility of the test solutions were maintained throughout the incubation period.

In aqueous solution (at 25°C), chlorophacinone is photolysed with a mean DT₅₀ value of 0.62 days under artificial sunlight. Based on the artificial-sunlight DT₅₀ values for buffer solution DT₅₀ (0.78 days) following continuous “Suntest” irradiation corresponded to **2.2 days natural** summer sunlight at latitude 50°N and in relation to the pond water DT₅₀ (0.45 days), following continuous “Suntest” irradiation, corresponded to **1.3 days** natural summer sunlight at latitude 50°N, both based on standard calculations. Reliability 1.

PHOTO-DEGRADATION ON A SOIL SURFACE

Soil photolysis according to US EPA Pesticide Assessment Guidelines, Subdivision N, Paragraph 161-3. The route and rate of photo-degradation of ¹⁴C-chlorophacinone was investigated on a soil surface (sandy clay loam) exposed to an artificial light source. During the exposure period the lamp intensity ranged from 3.7 4.3 x 10⁵ W/cm² (lamp rated at 400 to 765 W/m²). Natural sunlight on a clear sunny day at the test facility provided an intensity of 3.0 to 3.6 x 10⁵ W/cm². Exposure cycle consisted of a 12 hour light/dark exposure periods. The recovery of applied radioactivity from the individual exposed soil samples ranged from 42.1 to 122.7% AR (average 88.6%) over the entire study period, 30 days. Over the period 0 to 5 days, the recovery of applied radioactivity from the individual samples ranged from 95.9 to 122.7% AR (average 107%). From 5 days and onwards the recovery of applied radioactivity declined from 97.9% to 49.5% AR, this decline is considered due to incomplete recovery of evolved volatile components (i.e. carbon dioxide) due to inadequacies in the experimental design (see trapping procedure described in Doc. IIIA 7.2.2.4-01). The recovery of applied radioactivity from the individual dark control soil samples ranged from 94.3 to 121.0% AR (average 106%), indicating a complete mass balance for these sample types. The majority of the applied radioactivity was extractable from the soil and the levels observed steadily declined from 97.8% AR initially to 44.1% after 30 days. The amount of soil NER observed was minimal and accounted for a maximum of 1.5% AR in the exposed samples. Evolved volatile components were potentially significant (*ca* 50%). Chlorophacinone quickly photo-degraded on a soil surface when exposed to an artificial light source, with the best fit first order DT₅₀ value of chlorophacinone in soil at 25°C, corrected for the degradation observed in the dark controls was determined to be 4.1 days. The corresponding DT₉₀ value was 32.1 days. To reflect an average EU outdoor temperature of 12°C the degradation rates have been converted using the Arrhenius equation with a default activation energy of 54.0 kJ/mol. Converted to a temperature of 12°C the DT₅₀ and DT₉₀ values for the photo-degradation of Buckeystown sandy clay loam soil are 11.1 and 86.8 days, respectively.

Figure 1: Postulated photo-degradation pathway for chlorophacinone on a soil surface.



Photolysis of chlorophacinone on a soil surface proceeds rapidly with a DT_{50} of 11.1 days at an equivalent temperature of 12°C (based on DT_{50} at 25°C). Degradation of chlorophacinone results in the formation of a major metabolite o-phthalic acid (37.1% AR), carbon dioxide (potentially 50% AR) and three minor degradation products ($< 10\%$ AR). Chlorophacinone is steadily degraded in soil under aerobic conditions in the dark, with degradation leading primarily to the formation of carbon dioxide. In the presence of light, soil degradation is more rapid however the route of degradation is unaffected. Reliability 2.

TRANSFORMATION AND FATE IN AIR

The estimation of photochemical oxidative degradation of chlorophacinone (unpublished). QSAR estimation performed using the Atmospheric Oxidation Program v1.90 (AOPWIN) using the Atkins method based on structural relationships. The half-life and rate constant for the photochemical oxidative degradation of chlorophacinone in air via the hydroxyl reaction was estimated to be 14.3 hours and $9.00 \times 10^{-12} \text{ cm}^3 \text{ molecule}^{-1} \text{ s}^{-1}$, respectively (based on 1.5×10^6 OH radicals per cm^3). Chlorophacinone does not have any olefinic or acetylenic bonds and therefore it is unlikely that there is a significant photochemical oxidative degradation of chlorophacinone in air via the ozone.

The estimated half-life for the hydroxyl reaction in air is 14.3 hours. Furthermore, the vapour pressure of chlorophacinone as determined by OECD guideline no. 104 is $4.76 \times 10^{-4} \text{ Pa}$ (22.8°C) and Henry's law constant is $0.013725 \text{ Pa}\cdot\text{m}^3\cdot\text{mol}^{-1}$ (based on a water solubility of 13.0 mg a.s/l). Therefore chlorophacinone is not expected to volatilise to air in significant quantities. In conclusion, significant amounts of chlorophacinone are not likely to volatilise or persist in air. Reliability 1.

5.1.2 Biodegradation

5.1.2.1 Biodegradation estimation

Not relevant for this dossier.

5.1.2.2 Screening tests

The biodegradation of chlorophacinone has been investigated in laboratory studies under aerobic conditions. A summary of the studies conducted is provided in the table below:

The ready biodegradability of chlorophacinone (purity 99.77%) was investigated under aerobic conditions at a mean temperature of 22°C in the dark over a period of 28 days. The inoculum used was aerobic activated sewage sludge from a treatment plant (Füllinsdorf, Switzerland) treating predominantly domestic wastewater. The ThODs of the reference and test materials were calculated to be 1.67 and 2.13 mg O₂/mg, respectively. The percentage of biodegradation of the test material was calculated based on the ThOD of 2.13 mg O₂/mg. In the procedural control, the reference material (sodium benzoate) was biodegraded to the extent 85% after 14 and 28 days exposure, thus confirming the suitability of the inoculum and test conditions. The percentage of biodegradation observed in the toxic controls was calculated based on the ThOD of both the reference and test materials. The biodegradation of the reference material observed in the toxic control was 34% after 14 days. The test material did not have an inhibitory effect on the activated sewage sludge microorganisms (> 25% difference of procedural controls). Measurements taken at the end of the incubation period, showed that the pH in the test vessels was maintained during the study (pH~7.4-7.9). No significant biodegradation of chlorophacinone was observed after an incubation period of 28 days, consequently, chlorophacinone can not be considered readily biodegradable under the conditions of the test.

In the environment, chlorophacinone is not readily biodegradable according to the conditions of test OECD 301F (manometric respirometry test). An investigation into the inherent biodegradability was not carried out since the notifier assumed that chlorophacinone is not inherently biodegradable. It has also been assumed by the notifier that chlorophacinone is not likely to be biodegradable in biological sewage treatments either under aerobic or under anaerobic conditions.

As a conclusion, chlorophacinone is not biodegradable under environmentally relevant conditions or expected to be biodegradable during sewage treatment processes. Reliability 1.

5.1.2.3 Simulation tests

5.1.3 Summary and discussion of degradation

5.2 Environmental distribution

Biotic degradation in soil


Aerobic degradation in soil

The aerobic degradation in soil (initial study) was performed following US EPA Pesticide Assessment Guidelines, Subdivision N, Paragraph 162-1. As reference materials phthalic acid and chlorophenyl-phenyl acetic acid were utilized. The route and rate of aerobic degradation of Indan-¹⁴C-chlorophacinone (purity above 99%) was investigated in one soil (sandy clay loam: sand 56%, silt 21% and clay 23%; o.c. 1.2%) of US origin in the dark under laboratory conditions at a temperature of 24 to 26°C and moisture content of 75% field capacity (1/3 bar moisture). The microbial viability of the soils was determined at the start and end of the study. In order to further investigate the effect of the experimental design on the recovery of evolved volatile components, the experiment was repeated using a fresh batch of soil sourced from the same location (textural classification on re-sampling was sandy loam sand 71%, silt 22.3% and clay 7%; 1.0%).

Recovery of applied radioactivity from the original soil samples ranged from 72 to 101% AR (average 92%). The recovery of the evolved volatile components was improved following modifications to the experimental design. The majority of the applied radioactivity was extractable from the soil at all sampling intervals. Significant levels of carbon dioxide were evolved and were potentially as high as 65% after 182 days. The level of soil NER (Non Extractable Residues) observed did not exceed 11% AR. The level of chlorophacinone observed steadily declined with a biphasic degradation profile. A DT₅₀ value of 128 days was determined for the original soil samples, at an equivalent temperature of 12°C. Degradation of chlorophacinone did not lead to the formation of any significant metabolites (i.e. > 10% AR). Several minor metabolites (i.e. < 10% AR) were observed.

The best fit first order DT₅₀ value of chlorophacinone in soil was determined to be 47.3 days for a sandy clay loam soil at 25°C and the corresponding DT₉₀ value was > 200 days. To reflect an average EU outdoor temperature of 12°C the degradation rate has been converted using the Arrhenius equation with a default activation energy of 54.0 kJ/mol, in this fashion, the DT₅₀ value for Buckeystown sandy clay loam soil was 128 days.

Figure 2: Postulated degradation pathway for chlorophacinone in aerobic soil



The biotic degradation of chlorophacinone in moist soil has been investigated in two laboratory studies. A summary of the studies conducted is provided in the table below:

Laboratory studies investigating the degradation of chlorophacinone in soil (aerobic conditions)

Guideline / Test method	Soil type	Data range (days)	Moisture content	Temperature	Degradation parameters (days)			Reference
					DT ₅₀	DT ₉₀	Regression parameters	
US EPA Pesticide Assessment Guidelines, Subdivision N, Paragraph 162-1	Buckeystown (US) Sandy clay loam (pH~7.0, oc 1.18%)	0-182	75% 1/3 bar	25°C	47.3	> 200 ¹	1 ST order (Y = C ₀ x exp(-kt)) C ₀ = 93.508, k = 0.01466, R ² = 0.967	Spare, W., 1994
			--	(12°C calc)	128	--	--	--
	Buckeystown (US) Sandy loam (pH~7.2, oc 0.99%)	0-70	75% 1/3 bar	25°C	17.1	--	1 ST order (Y = C ₀ x exp(-kt)) C ₀ = 88.633, k = 0.04063, R ² = 0.955	Spare, W., 1994
		30-70			--	125 ¹	1 ST order (Y = C ₀ x exp(-kt)) C ₀ = 45.745, k = 0.01846, R ² = 0.999	

¹DT₅₀ (or DT₉₀) value was not demonstrated experimentally, result obtained by extrapolation.

In soil under dark aerobic conditions in the laboratory (12°C extrapolated from 25°C), chlorophacinone is degraded steadily with an estimated DT₅₀ value of 128 days. Degradation of chlorophacinone results predominantly in the formation of carbon dioxide (61.0% AR after *ca* 100 days) (mineralization). Metabolites (including o-phthalic acid and p-chlorophenyl phenyl acetic acid) do not exceed 10% AR at any sampling interval. Soil non-extractable residue (NER) comprises 9.0% AR after *ca* 100 days. Reliability 2.

5.2.1 Adsorption/Desorption

Adsorption/desorption screening test

Four soil types were used (clay, sand, sandy clay loam and loam). For the preliminary investigations, a stock solution of chlorophacinone in calcium acetate solution was prepared at a concentration of 3.0 µg/ml by adding the test material dissolved in acetonitrile. For the definitive study, a stock solution of the test material was prepared by adding chlorophacinone dissolved in acetonitrile (2310 µl) to 0.01M calcium acetate solution (826 ml). The working solutions were prepared at concentrations of 0.17, 0.34, 0.65, 1.24 and 2.56 µg/ml by diluting with further blank calcium acetate solution.

Freundlich adsorption isotherms were determined for all soils over an actual concentration range of 0.17 to 2.56 µg/ml. The adsorption of chlorophacinone to soil gave a good correlation to the Freundlich equation (correlation 0.99 to 1.00).

The sorption properties of chlorophacinone have been investigated in a laboratory adsorption/desorption study and a summary of the results is provided in the table below:

Chlorophacinone is strongly adsorbed to soil. The amount of chlorophacinone adsorbed to soil was > 36.6 to > 85.2% during the adsorption phase. The Freundlich soil sorption coefficient normalised for organic carbon content (K_{oc}) was 15,600 to 136,000 ml/g. This result indicates chlorophacinone

as 'non mobile' according to the SSLRC classification index. The Freundlich exponent (1/n) ranged from 1.145 to 1.231.

The log *n*-octanol-water partition coefficient (log K_{ow}) is a measure of the hydrophobicity of a chemical. As such, log K_{ow} is a key parameter in the assessment of environmental fate. Estimations of the K_{oc} based on the K_{ow} applying (Q)SARs for soil and sediment would be several orders of magnitude lower than the experimental value retrieved in the adsorption/desorption screening test (K_{oc} from 136,000 to 15,600). The drastic difference reflects that other processes are involved apart from lipophilicity. As a conclusion, adsorption to soil does not depend only on the organic carbon content. Reliability 2.

5.2.2 Volatilisation

Its vapour pressure is low, $4.76 \cdot 10^{-4}$ Pa at 23°C and its Henry's Law Constant as well ($0.013725 \text{ Pa} \cdot \text{m}^3 \cdot \text{mol}^{-1}$), hence the atmospheric compartment is not usually contaminated.

5.2.3 Distribution modelling

Not relevant for this dossier.

5.3 Aquatic Bioaccumulation

Table 22: Summary of relevant information on aquatic bioaccumulation

Method	Results	Remarks	Reference
Absorption, distribution, metabolism and excretion study Single oral dose study in the rat The study was conducted prior to the availability of guidelines for this study type. However, the methodology is similar to US EPA 85-1 guidelines	The excretion studies indicate that 90% of the compound is recovered from faeces within 48 hours after oral administration and 100% within 4 days. The compound is absorbed, enters the enterohepatic circulation and then is excreted through the faeces. The urinary elimination and CO_2 elimination is less than 1% after 4 days.	No metabolite identification was undertaken in this study	Belleville M.J., (1977)
Absorption, distribution, metabolism and excretion study Single oral dose study in the rat	Excretion was incomplete 168 hours after a single oral dose at 2 mg chlorophacinone/kg to male rats. Faecal elimination was major route of excretion, urine accounted for less than 1% of administered dose. Unchanged chlorophacinone was eliminated in the faeces (19.6% faecal radioactivity). Two major metabolites, accounting for 46% faecal radioactivity were identified as mono-hydroxylated analogues of chlorophacinone		Needham, D and Russell, N., (2004)

5.3.1 Aquatic bioaccumulation

5.3.1.1 Bioaccumulation estimation

Two studies on absorption, distribution, metabolism and excretion were performed with chlorophacinone in rats (see section 3.1.). A summary is given below.

Absorption, distribution, metabolism and excretion studies in the rat using ¹⁴C-labeled chlorophacinone. Single oral dose study in the rat. Methodology similar to US EPA 85-1. Purity of the test material not stated in the report. The excretion studies indicate that 90% of the compound is recovered from faeces within 48 hours after oral administration and 100% within 4 days. The blood half-life for elimination was 10.2 h. Excretion predominantly faecal. The study of the degradation of the compound from extracted faeces indicates that the material is excreted principally as metabolized rodenticide. Chromatographic evidence indicates that unchanged parent accounted for only a small component of the faecally eliminated radioactivity. No metabolite identification was undertaken in this study. The compound is absorbed, enters the enterohepatic circulation and then is excreted through the faeces. The urinary elimination and CO₂ elimination is less than 1% after 4 days. Reliability 2.

Another study was conducted with ¹⁴C-chlorophacinone: Metabolism in the rat following oral dosing. Absorption, distribution, metabolism and excretion study. Purity of the test material (99.58%). Single oral dose study in rat. A single group of eight male rats were fed by oral gavage a nominal dose of 2 mg/kg food with a post-exposure period of 168 hours. Three rats were killed on health grounds 72 hours after dosing. None of the other five showed adverse reactions to dose administration. 78% of the radioactivity appeared in faeces and less 1% in urine after 7 days. 8% of dose was found in the carcass at necropsy 7 days after dosing indicating that excretion was incomplete. Overall recovery was 91%; the discrepancy with the 100% excretion at 96 h from the previous study (6.2-01) was not explained.

Metabolite identification was carried out on the 0-48 hour faecal samples since these contained the highest concentration of radioactivity. Aliquots were extracted with one of three solvents, methanol, ethyl acetate or methyl tri-isobutyl ether (MTBE). Methanol was most efficient extracting 83.7% of faecal metabolites. Solvent concentrates were analysed by HPLC, which showed up five metabolites, the major one co-eluting with the chlorophacinone standard. Some of the minor metabolites co-eluted with impurities present in the radiolabelled chlorophacinone. An aliquot of faeces was extracted three times in methanol whose extract contained 85.6% of total radioactive residues. After a further clean-up it became 90% of total radioactive residues and a further non-extractable 12.5% remaining in the faecal pellet. Aliquots of the methanol extract were evaporated to near dryness to remove organic solvents, the results showed no significant difference in metabolite profile suggesting that there were no glucuronide or sulphate conjugates present. A second MTBE extract was prepared. The process produced three ions for the three major radiolabelled compounds found in faecal extracts. The three ions had retention times of circa 18.6, 16.9 and 15.6 minutes. Mass spectrometry and chromatographic data confirmed the first to be chlorophacinone and the other two metabolites hydroxylated analogues of chlorophacinone (the first one of the analogues with hydroxylation occurring on the indandione portion of the molecule and the second one on the biphenyl portion of the molecule).

Metabolite quantification. Faecal samples from the five surviving animals to termination were pooled and extracted in methanol. The extract contained 81.8% of the faecal radioactivity with 18.2% remaining in the residue. The three major metabolites identified were chlorophacinone and hydroxylated products accounting for 80.2% of the radioactivity in the faeces (unchanged chlorophacinone accounted for 19.6% of faecal radioactivity and indicated that 15.5% of

administered radioactivity was present in faeces as unchanged parent molecule; the hydroxylated analogues accounted for 46% of radioactivity eliminated in faeces which corresponds to a 36.2% of the administered dose). Further attempts to identify the minor metabolites were unsuccessful since no meaningful spectra could be obtained.

Excretion was incomplete 168 hours after a single oral dose at 2 mg chlorophacinone/kg to male rats. Faecal elimination was major route of excretion, urine accounted for less than 1% of administered dose. Unchanged chlorophacinone was eliminated in the faeces (19.6% faecal radioactivity). Two major metabolites, accounting for 46% faecal radioactivity were identified as mono-hydroxylated analogues of chlorophacinone. Reliability 2.

5.3.1.2 Measured bioaccumulation data

Measurements of aquatic bioconcentration of chlorophacinone have not been performed. According to the TGD; ECB 2003, the BCF for fish can be predicted from the relationship between K_{ow} and BCF in cases where measured BCF values are not available. For substances with a $\log K_{ow}$ lower than 6 it is generally agreed that a linear relationship exists for chemicals which are not biotransformed. The linear model developed by Veith *et al.* (1979) can be used:

$$\log BCF = 0.85 \cdot \log K_{ow} - 0.70$$

$$\log BCF_{fish} = 0.85 \cdot 2.42 - 0.70; \quad BCF_{fish} = 22.75 \text{ l/kg}$$

Having checked these studies and acknowledging that chlorophacinone has a $\log P_{ow} = 2.42$ ($pH \sim 7$ at 23°C); value below 3, it is accepted that chlorophacinone has a relatively low potential to bioaccumulate. No studies on the bioconcentration potential of chlorophacinone in aquatic and terrestrial environment have been supplied by the applicant to confirm its low bioaccumulation potential.

5.3.2 Summary and discussion of aquatic bioaccumulation

5.4 Aquatic toxicity

Table 23: Summary of relevant information on aquatic toxicity

Method	Results	Remarks	Reference
Short-term toxicity to fish US EPA FIFRA 72-1 comparable to OECD 203	LC ₀ (96h) = 0.22 mg a.s/l LC ₅₀ (96h) = 0.45 mg a.s/l LC ₁₀₀ (96h) = 1.0 mg a.s/l	Flow-through <i>Onchorhynchus mykiss</i>	Machado, M.W. (1992a)
Short-term toxicity to fish OECD 203	LC ₀ (96h) = 0.36 mg a.s/l LC ₅₀ (96h) = 0.71 mg a.s/l	Flow-through <i>Lepomis macrochirus</i>	Machado, M.W. (1992b).
Acute toxicity to invertebrates	EC ₀ (48 h) = 0.31 mg a.s/l EC ₅₀ (48 h) = 0.64 mg a.s/l	<i>D. magna</i> Measured	Putt, A.E. (1992).

OECD 202		concentrations	
Acute and long-term toxicity to algae OECD 201	NOE _r C = NOE _b C = 0.72 mg a.s/l E _b C ₅₀ = 1.7 mg a.s/l (calculated from the area under the growth curve) E _b C ₅₀ = 2.2 mg a.s/l (calculated from growth rate)	Static. Endpoint: growth inhibition <i>Desmodesmus subspicatus</i> (former <i>S. subspicatus</i>)	Peither, A. (2003).
Activated sludge OECD 209	EC ₅₀ (3 h) > 1000 mg a.s/l EC ₈₀ (3 h) > 1000 mg a.s/l NOEC (EC ₁₅) (3 h) = 775 mg a.s/l	Static. Respiration inhibition. All EC and NOEC values above the water solubility limit	Peither, A. (2003).

5.4.1 Fish

5.4.1.1 Short-term toxicity to fish

In two tests performed under flow-through conditions, the 96-hour LC₅₀ were 0.45 and 0.71 mg a.s/l for *Oncorhynchus mykiss* and *Lepomis macrochirus*, respectively (mean measured concentrations). These two studies conform to current guideline requirements and exposure concentrations were verified analytically.

In the first test the author determined an LC₅₀ for rainbow trout (*Oncorhynchus mykiss*) of 0.45 mg a.s/l (95% confidence limits of 0.42 to 0.49 mg a.s/l) based on mean measured concentrations and using probit analysis. The acute toxicity test was performed according to US EPA FIFRA 72-1, comparable to OECD guideline n° 203.

Twenty fish (Rainbow trout) (ten per replicate) were tested for 96 h under flow-through conditions. A preliminary test was conducted in order to determine the toxically relevant range. All fish were fed a dry commercial pelleted food daily ad libitum except during the 48 h prior to and during the definitive test. No mortality occurred in the fish test population during the two days prior to testing. The test was performed at five nominal concentrations of the test material (1.0, 0.60, 0.36, 0.22 and 0.13 mg a.s/l), a solvent control and a dilution water control. All the mean measured concentrations were above 80% of the nominal concentrations. The 96-hour LC50 value was 0.45 mg a.s/l based on mean measured concentrations; LC0 (96 h) = 0.22 mg a.s/l and LC100 (96 h) = 1.0 mg a.s/l. Temperature between 11 and 13°C, pH~6.7-7.2, dissolved oxygen above 60% and a 16-h photoperiod. Test fish were 36-54 mm and a mean wet weight of 1.1 g. The age of the organism was not reported. All relevant parameters were within the ranges dictated by the guideline. Reliability 1.

In the second test, the author determined an LC₅₀ for bluegill sunfish (*Lepomis macrochirus*) of 0.71 mg a.s/l (95% confidence limits of 0.63 to 0.83 mg a.s/l) based on mean measured concentrations and using probit analysis. The acute toxicity test was performed according to US EPA FIFRA 72-1, comparable to OECD guideline n° 203.

US EPA FIFRA 72-1, comparable to OECD 203 (Fish, acute toxicity test). Twenty fish (ten per replicate) Bluegill sunfish were tested for 96 h under flow-through conditions. A preliminary test was conducted in order to determine the toxically relevant range. All fish were fed a dry commercial pelleted food, *ad libitum*, daily except during the 48 h prior to, and during the definitive

test. No mortality in the fish test population during the two days prior to testing. The test was performed at five nominal concentrations of the test material (1.2, 0.72, 0.43, 0.26 and 0.16 mg a.s/l), a solvent control and a dilution water control. Mean measured concentrations (0.82, 0.52, 0.36, 0.24 and 0.11 mg a.s/l) were ranged from 68-92 % of the nominal concentrations. The 96-hour LC₅₀ value was 0.71 mg a.s/l based on mean measured concentrations. LC₀ = 0.36 mg a.s/l. 100% mortality was not reached. Temperature between 21 and 22°C, pH~7.0-7.3, dissolved oxygen above 60% and a 16-h photoperiod. Test fish were 36-54 mm and a mean wet weight of 1.1 g. The age of the organism was not reported. All relevant parameters were within the ranges dictated by the guideline. Reliability 1.

5.4.1.2 Long-term toxicity to fish

Information on long-term toxicity on aquatic vertebrates has not been provided but, the available information is considered enough for carrying out a proper risk assessment.

5.4.2 Aquatic invertebrates

5.4.2.1 Short-term toxicity to aquatic invertebrates

The author determined an EC₅₀ (24 h) > 820 µg/l and an EC₅₀ (48 h) = 640 µg/l (95% confidence limits of 540 to 820 µg/l) based on mean measured concentrations and using probit analysis. The acute toxicity test was performed according to US EPA FIFRA 72-2, comparable to OECD guideline n° 202 (I) (*Daphnia* sp., Acute Immobilisation Test and Reproduction Test) and EU C.2.

Twenty invertebrates (*Daphnia magna*) (ten per replicate) were tested for 48 hours under flow-through conditions. A preliminary test was conducted in order to determine the toxicologically relevant range. Daphnids were not fed during the 48-hour definitive exposure. 5 concentrations of the test material (nominal: 850, 510, 310, 180 and 110 µg/l), one solvent control and one dilution water control. All the mean measured concentrations were above 80% of the nominal concentrations. The 48-hour EC₅₀ value was 0.64 mg a.s/l. Temperature of the test ranged between 19 and 22°C, pH~8.0-8.2, dissolved oxygen above 60% and a 16-h photoperiod. Test aquatic invertebrates were ≤ 24 hours old at the beginning of the test. All relevant parameters were within the ranges dictated by the guideline.

D. magna was similar in sensitivity to fish, with a 48-hour EC₅₀ of 0.64 mg a.s/l recorded under flow-through conditions. The endpoint was based on immobilisation and on mean measured concentrations of chlorophacinone in the test media. Reliability 1.

5.4.2.2 Long-term toxicity to aquatic invertebrates

No data have been provided on long-term toxicity to aquatic invertebrates but, the available information is considered enough for carrying out a proper risk assessment.

5.4.3 Algae and aquatic plants

The author determined in a 72-hour algal growth inhibition test with *Desmodesmus subspicatus* (formerly known as *Scenedesmus subspicatus*) an E_bC₅₀ (72 h) = 1.7 mg chlorophacinone/l and an E_rC₅₀ (72 h) = 2.2 mg a.s/l (95% confidence limits of 0.7 – 9.1 mg/l). The NOEC was 0.72 mg a.s/l

with respect to both biomass yield, NOE_bC , and specific growth rates, NOE_rC based on mean measured concentrations and using probit analysis for the $EC_{50}s$ and the Dunnett's t-test to determine significant differences from solvent control to locate the NOECs. The growth of the green algal species *Desmodesmus subspicatus* was investigated in a 72-hour static test according to OECD 201 (Alga, Growth Inhibition Test) and EU method C.3.

The test concentrations were based on the results of a range-finding test without GLP. Five nominal concentrations 3.5, 1.6, 0.72, 0.35 and 0.16 mg a.s/l in parallel with one control and a solvent control group. The measured concentrations varied in the range of 84 to 88% of the nominal values. The 72-hour E_bC_{50} value was 1.7 mg a.s/l and the value of E_rC_{50} was 2.2 mg a.s/l based on the nominal concentrations of the active substance. Temperature of the test was between 22-23°C, pH~7.9 to 8.0 at start to 8.1 to 8.6 at end. All relevant parameters were within the ranges dictated by the guideline.

The new OECD algal inhibition Guideline (OECD 201, 2006) contains 3 validity criteria. One of these is a requirement for cell density to increase by a factor of at least $\times 16$ in the control vessels in 72 hours. The second one is "The mean coefficient of variation for section-by-section growth rates must not exceed 35%". The mean coefficient of variation for the three 1-day sections in this study was 7.8%. And the third one "The coefficient of variation of average specific growth rates during the whole test period in replicate control cultures must not exceed 7% in tests with *Desmodesmus subspicatus*". The coefficient of variation for the control replicates over the entire study duration was 0.81%. The algal study performed with chlorophacinone may therefore be considered valid according to all three criteria. Reliability 1.

From all the aquatic toxicity endpoints for chlorophacinone before mentioned, fish represent the most sensitive of the three aquatic trophic levels tested and the LC_{50} (96h) = 0.45 mg a.s/l for *O. mykiss* serves as the key endpoint for the aquatic risk assessment.

5.4.4 Other aquatic organisms (including sediment)

The effect of chlorophacinone on aerobic biological sewage treatment processes was assessed by determining inhibition of respiration of the micro-organisms present in activated sludge following three-hour contact. The following nominal concentrations of the active substance were tested: 10, 32, 100, 320 and 1,000 mg a.s/l. In addition, two controls and three different concentrations of the reference substance 3,5-dichlorophenol (5, 16 and 50 mg a.s/l) were tested in parallel. The results of these treatments confirmed the suitability of the activated sludge. No adverse effects were detected below the water solubility limit of the substance. Therefore, the water solubility limit has been used for the $PNEC_{microorganisms}$ derivation instead of the nominal concentration.

The maximum inhibition of respiration recorded was less than 20% at a much higher concentration than the water solubility limit what means that chlorophacinone does not appear to have significant negative effects for the microbial activity of the STP sludges. Reliability 1.

5.5 Comparison with criteria for environmental hazards (sections 5.1 – 5.4)

Chlorophacinone is classified for the environment in Annex 1 of Council Directive 67/548/EEC.

Current classification of Chlorophacinone for the environment under the DSD

Classification	as detailed in Directive 67/548/EEC
Class of danger	N
R phrases	R50/53: Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
S phrases	S60: This material and its container must be disposed of as hazardous waste S61: Avoid release to the environment. Refer to special instructions/safety data sheets.

According to Regulation (EC) No 1272/2008 and Regulation (EU) No 286/2011GHS pictogram: GHS09Signal word: WarningHazard statements:

Aquatic acute 1: H 400 Very toxic to aquatic life

Acute M-factor 1

Aquatic chronic 1: H410 Very toxic to aquatic life with long lasting effects

Chronic M-factor 1

Precautionary statements:

P273 Avoid release to the environment

P391 Collect spillage

P501 Dispose of contents/container to...

5.6 Conclusions on classification and labelling for environmental hazards (sections 5.1 – 5.4)

On basis of study results from studies presented in the dossier classification of chlorophacinone was proposed according to principles detailed in Annex VI of Council Directive 67/548/EEC (with amendments and adaptations).

Regarding the environmental effects, the acute toxicity of chlorophacinone in fish, daphnia and algae was investigated, so that sufficient data are available to allow classification and labelling of the active ingredient according to the requirements of Annex VI of directive 67/548/EEC. The proposed classification and labelling (R50) is based upon the lowest acute toxicity testing in aquatic organisms (fish LC₅₀ (96 h) = 0.45 mg a.s/l). Chlorophacinone was also tested for ready biodegradability under aerobic conditions at a mean temperature of 22°C in the dark over a period of 28 days (inoculum used: aerobic activated sewage sludge from a treatment plant). It was concluded not being readily biodegradable. An investigation into the inherent biodegradability was not carried out since the notifier assumed that chlorophacinone is not inherently biodegradable. It has also been assumed by the notifier that chlorophacinone is not likely to be biodegradable in biological sewage treatments either under aerobic or under anaerobic conditions. The conclusion

was that chlorophacinone is not biodegradable under environmentally relevant conditions or expected to be biodegradable during sewage treatment processes (R 53).

According to Regulation (EC) No 1272/2008 since the aquatic toxicity is ≤ 1 mg a.s/l and the substance is not rapidly degradable, the substance is classified as Acute Category 1 and Chronic Category 1.

In respect of Regulation (EU) No 286/2011 the classification is Category Acute 1 and Category Chronic 1. Since there is only one NOEC available, a comparison was performed with that NOEC and the surrogate system. The most restrictive classification was chosen. With the algae NOErC = 0.72 mg a.s/l Category Chronic 2 should apply. On the other hand, applying the surrogate system, Category Chronic 1 should apply. This is the most restrictive one category. Conclusion: chlorophacinone is classified as Category Acute 1 and Category Chronic 1.

6 OTHER INFORMATION

Teratology study of the test item Warfarin sodium with rats (Kubaszky, R., 2009)

The objective of the study was to assess the effects of Warfarin Sodium on pregnant females and on the developing conceptuses during pregnancy in Crl:(Wi) BR-Wistar Rats after oral administration at three dose levels (0.125, 0.150, 0.200, mg/kg/day) from day 6 up to and including day 15 post coitum (T.P. 1) and from day 6 up to and including day 19 post coitum (T.P. 2). Two additional extra high dose groups of 0.250 mg/kg/day of 12 dams were added for both T.P. 1 and T.P. 2, to demonstrate clear maternal toxicity. The dose volume was 5 ml/kg.

The clinical symptoms, mortality, necropsy findings; body weight, body weight gain, and reproduction data of the dams were recorded and evaluated. The body weight of the foetuses was measured; the placentas were examined externally; the external, visceral and skeletal abnormalities of foetuses were recorded and evaluated. This nonclinical exploratory laboratory study was performed in compliance with OECD Guideline for Testing of Chemicals (OECD 414/22 January 2001).

Nine dams died in the T.P.1 treatment period group; two at 0.150 mg/kg, two at 0.200 mg/kg and five at 0.250 mg/kg. There were five dead and four moribund dams in the T.P. 2 group. One moribund dam was in the 0.150 mg/kg dose group. Five dead and three moribund dams were in the 0.250 mg/kg dose group. The death or euthanasia of the dams occurred between gestation days 14 and 17 and in one case on gestation day 19. The mortality was ascribed to treatment.

Clinical signs such as piloerection, paleness, reduced activity and vaginal bleeding and open vaginal orifice were recorded for the animals subsequently found dead or sacrificed. Vaginal bleeding, open vaginal orifice, paleness, haemorrhage or piloerection were recorded for some surviving females in the 0.150 mg/kg, 0.200 mg/kg and 0.250 mg/kg T.P. 1 groups and 0.200 mg/kg T.P.2. These changes were attributed to treatment. The body weight, body weight gain, gravid uterine weight, corrected body weight, corrected body weight gain of dams were not affected by treatment.

At necropsy, treatment related gross pathology alterations included uterus filled with blood, bloody staining around the vaginal orifice, intestinal bleeding, pale organs.

There was no difference between the experimental groups in the number of corpora lutea, pre- or post implantation loss, number of implantation or viable foetuses. Sex ratio was not adversely affected by maternal treatment. Mean foetal weight was similar in all groups.

External examination of foetuses showed one litter with 4 foetuses with short nose and wide frontal bone in the 0.150 mg/kg T.P.1 group (confirmed at skeletal examination). This litter was not included in the statistical evaluation. It is concluded that these malformations were attributable to treatment with Warfarin Sodium.

The incidence of greenish discolouration of placentas was significantly higher in the 0.150 mg/kg, 0.200 mg/kg and 0.250mg/kg T.P.1 groups and was significantly higher in the T.P. 2 in the 0.200 mg/kg dose group. The incidence of pale placentas was significantly higher in the T.P. 1 0.250 mg/kg dose group. These alterations were considered to be due to treatment.

The incidence of external and visceral foetal haemorrhages was higher in all treated groups than the respective control groups; this was attributed to the known anticoagulant effect of the test item.

At visceral examination, an increased incidence of central cataract (confirmed by histopathology) was observed (one foetus in the T.P. 1 0.200 mg/kg dose group, 2 at 0.150 mg/kg and 4 at 0.200 mg/kg dose levels in the T.P. 2 group). This rare malformation was considered to be an effect of treatment with Warfarin Sodium. No statistical differences in skeletal observations were attributed to treatment. However, one litter in the 0.150 mg/kg T.P.1 group showed skull malformations which were attributed to a teratological effect of the test item. At 250 mg/kg in the T.P.2 group, there was an indication of reduced skull ossification.

In conclusion, under the conditions of this study it is considered that warfarin sodium administered orally to the pregnant CrI:(Wi) BR-Wistar Rats caused adverse effects in the foetus. These included subcutaneous haemorrhage at all dose levels and visceral haemorrhage at 0.200 mg/kg in T.P.2 group. Foetal abnormalities ascribed to treatment included central ocular cataract in the 0.150 mg/kg T.P.2 and 0.200 mg/kg T.P.1 and T.P.2 groups, skull malformations of short nose and wide frontal bones in the 0.150 mg/kg dose T.P.1 group and an indication of reduced ossification of skull bones in the T.P.2 group at 250 mg/kg. Treatment was associated with increased incidence of maternal death and bleeding from the vagina in later pregnancy, with necropsy findings of blood in the uterus, at 0.150 mg/kg and above.

NO(A)EL maternal toxicity: 0.125 mg/kg bw/day

NOEL developmental toxicity: <0.125 mg/kg bw/day

NOEL teratogenicity: 0.125 mg/kg bw/day

STUDY CODE: 07/396-105P Page 11 of 363

7 REFERENCES

HUMAN HEALTH

Belleville, M.J. Absorption, distribution, metabolism and excretion studies in the rat using ¹⁴C-labeled Chlorophacinone. Lipla S.A. Research Centre, Lyon, France. No laboratory study identification number. Non-GLP/Unpublished.

Betbeder-Matibet A. 1981. Research on the Mutagenic Potential of Chlorophacinone Using the Ames Test. Lipla Bacteriology Laboratory, Centre de Recherches, Lyon, France. Laboratory report No: not stated. Non-GLP/Unpublished.

Bressot Perrin, H. 1999. Personal communication.

Curl, M. 2004. The Calculation of Henry's Law Constant for chlorophacinone. TSGE laboratory report no. 12-1-12.HL. Not GLP/Unpublished.

Depin, J.C. and Chavernac, G. 1986. LM 2219 Pharmacological approach. Research Centre, Lyonnaise Industrielle Pharmaceutique, 69359 Lyon Cedex, France. Report Number: No identification stated. Non GLP/Unpublished.

Fitzgerald G.B. 1990. Repeated Dose Dermal Toxicity: 21 Day Study – Sprague-Dawley Rats (Chlorophacinone). Toxicon Corporation, Woburn, MA. Laboratory report No: 90G-0726. GLP/Unpublished.

Fitzgerald G.B. 1990. Repeated Dose Dermal Toxicity (21-Day) Study – New Zealand Albino Rabbits (Chlorophacinone). Toxicon Corporation, Woburn, MA. Laboratory report No: 90G-0727. GLP/Unpublished

Hamada, N. 1992. 21-Day Dermal Toxicity Study in Rabbits with Chlorophacinone. Hazleton Washington Inc. Rockville, MD. Laboratory report No: HWA 2624-105. GLP/Unpublished.

Hamada, N. 1992. 21-Day Dermal Ranging Toxicity Study in Rabbits with Chlorophacinone. Hazleton Washington Inc. Rockville, MD. Laboratory report No: HWA 2624-106. GLP/Unpublished.

Hamada, N. 1992. 21-Day Dermal Ranging Toxicity Study in Rabbits with Chlorophacinone. Hazleton Washington Inc. Rockville, MD. Laboratory report No: HWA 2624-104. GLP/Unpublished.

Hardwick, T. and Russell, N. 2003. [¹⁴C]-Chlorophacinone: Rates of penetration through human skin using a flow through in vitro system. Covance Laboratories Ltd. Laboratory report No 2336/002-D1145. GLP/Unpublished

Hoffman, M. 1988. Melting point/melting range determination of chlorophacinone. Hazleton Laboratories America, Inc., laboratory report no. HLA 6001-221. GLP/Unpublished.

Hoffman, M. 1988. Vapor pressure determination of chlorophacinone (CPN). Hazleton Laboratories America, Inc., laboratory report no. HLA 6001-217. GLP/Unpublished.

Hoffman, M. 1988. Water solubility determination of chlorophacinone. Hazleton Laboratories America, Inc., laboratory report no. HLA 6001-216. GLP/Unpublished.

Holbert, M.S. 1991 Acute inhalation toxicity study of technical Chlorophacinone in rats. Stillmeadow, Inc., Sugar Land, Texas. Laboratory report No: 7436-90. GLP/Unpublished.

- Kramer, H., Marion, T. 2002. Melting point, bulk density, pH and accelerated stability of chlorophacinone. Covance Laboratories Inc., laboratory report no. 6372-110. GLP/Unpublished.
- Kramer, H., Marion, T. 2002. Water solubility of chlorophacinone. Covance Laboratories Inc., laboratory report no. 6372-109. GLP/Unpublished.
- Kramer, H., Marion, T. 2002. Octanol/water partition coefficient and dissociation constant of chlorophacinone. Covance Laboratories Inc., laboratory report no. 6372-111. GLP/Unpublished.
- Kubaszky, R., 2009. Teratology study of the test item Warfarin sodium with rats. CEFIC EBPF Rodenticide Working Group
- Lawlor, T.E. 1994. Mutagenicity Test with Chlorophacinone in the Salmonella – Escherichia coli/Mammalian-Microsome Reverse Mutation Assay with a confirmatory Assay. Hazleton Washington Inc., Vienna, Virginia. Laboratory report No: HWA 16030-0409R. GLP/Unpublished.
- Lilja, H.S. 1990. Single Dose Dermal Toxicity Study (Range Finding I) Chlorophacinone. Toxicon Corporation, Woburn, MA. Laboratory report No: 89G-0146A. GLP/Unpublished.
- Lilja, H.S. 1990. Single Dose Dermal Toxicity Study (Range Finding II) Chlorophacinone. Toxicon Corporation, Woburn, MA. Laboratory report No: 89G-0146B. GLP/Unpublished.
- Lilja, H.S. 1990. Single Dose Dermal Toxicity Study (Range Finding III) Chlorophacinone. Toxicon Corporation, Woburn, MA. Laboratory report No: 89G-0146C. GLP/Unpublished.
- Lilja, H.S. 1990. Single Dose Dermal Toxicity Study (LD50 I) Chlorophacinone. Toxicon Corporation, Woburn, MA. Laboratory report No: 89G-0146D. GLP/Unpublished.
- Lilja, H.S. 1989. Primary Dermal Irritation Study. Chlorophacinone. Toxicon Corporation, Woburn, MA. Laboratory report No: 89G-0147. GLP/Unpublished.
- Lilja, H.S. 1989. Primary Ocular Irritation Study. Chlorophacinone. Toxicon Corporation, Woburn, MA. Laboratory report No: 89G-0148. GLP/Unpublished.
- Lindemann, M. 2004. Screening of the thermal stability in air of chlorophacinone. RCC Limited, laboratory report no. 849162. GLP/Unpublished.
- Lindemann, M. 2004. Determination of the flammability of chlorophacinone. RCC Limited, laboratory report no. 849161. GLP/Unpublished.
- Lindemann, M. 2004. Determination of the relative self-ignition temperature of chlorophacinone. RCC Limited, laboratory report no. 849160. GLP/Unpublished.
- Lindemann, M. 2003. Determination of the surface tension of an aqueous solution of chlorophacinone. RCC Limited, report no. 849159. GLP/Unpublished.
- Lindemann, M. 2003. Expert statement on the explosive properties of chlorophacinone. RCC Limited, laboratory report no. 849158. GLP/Unpublished.
- Lindemann, M. 2003. Expert statement on the oxidising properties of chlorophacinone. RCC Limited, laboratory report no. 849157. GLP/Unpublished.
- Loken, R. 1988. Octanol/water partition coefficient determination of chlorophacinone Hazleton Laboratories America, Inc., laboratory report no. HLA 6001-218. GLP/Unpublished.

Mally C., and Porret-Blanc G. 1988. LD50 Evaluation of Chlorophacinone in Solution in PEG 300 Orally to Rats. Lipha Centre de Recherches, Lyon, France (Dates of experimental work: March 1, 1988- March 22, 1988). Unpublished report No.: 88.02.LM.91.RP2. GLP/Unpublished.

Mally, C., Porret-Blanc G and Lorgue, G. 1984. 3 Month Toxicity Study on Rats by Oral Method Chlorophacinone (LM-91). Lipha Centre de Recherches, Lyon, France. Laboratory report No: 84.05.LM.91.RPP. GLP/Unpublished.

Markiewicz, V.R. 1991. Antidotal Treatment Study Following Oral Exposure to Chlorophacinone in Rats. Hazleton Washington Inc. Laboratory report No 2624-103. GLP/Unpublished.

Murli, H. 1994. Mutagenicity test on Chlorophacinone in an in vivo mouse micronucleus assay. Hazleton Washington Inc. Vienna, Virginia. Laboratory report No: HWA 16030-0-455CO. GLP/Unpublished.

Needham, D and Russell, N. 2004. [14C]-Chlorophacinone: Metabolism in the rat following oral dosing. Covance Laboratories Ltd., UK. Laboratory report no. 2336/001-D1145. GLP/Unpublished.

Pesselman, R. 1990. Density determination of chlorophacinone (CPN). Hazleton Laboratories America, Inc., laboratory report no. HLA 6001-602. GLP/Unpublished.

Pesselman, R. 1990. Physical state determination of chlorophacinone (CPN). Hazleton Laboratories America, Inc., laboratory report no. HLA 6001-600. GLP/Unpublished.

Pesselman, R. 1990. Munsell color determination of chlorophacinone (CPN). Hazleton Laboratories America, Inc., laboratory report no. HLA 6001-599. GLP/Unpublished.

Pesselman, R. 1990. Odor determination of chlorophacinone (CPN). Hazleton Laboratories America, Inc., laboratory report no. HLA 6001-601. GLP/Unpublished.

Pesselman, R. 1991. Solubility determination of chlorophacinone. Hazleton Laboratories America, Inc., laboratory report no. HLA 6372-100. GLP/Unpublished.

Queche, P. 1999. NMR, MS, IR, UV/vis spectra. Chlorophacinone active ingredient. Lipha s.a., laboratory report no. ASCLOR100-99. Not GLP/Unpublished.

Reagan E. L. 1986. Acute oral LD50 of Chlorophacinone in Beagle Dogs. Food and Drug Research Laboratories, Inc., Waverly, NY. FDRL study No: 9122A.GLP/Unpublished

Shapiro, R. 1990. EPA Guinea Pig Sensitisation (Buehler). Product Safety Labs, East Brunswick, NJ. Laboratory report No: T-9990. GLP/Unpublished.

Stankowski, L. F. 1995 Structural Chromosomal Aberration Assay in Human Lymphocytes with Chlorophacinone (CPN). Pharmakon Research International, Inc., Waverly, PA. Laboratory report No: PH 324-LPT-001-94. GLP/Unpublished.

Tognucci, A. 2002. Determination of the boiling point/boiling range of chlorophacinone. RCC, laboratory report no. 844813. GLP/Unpublished.

Tyl, R.W., Marr, M.C. and Myers, C.B. 1994. Developmental toxicity Evaluation of Chlorophacinone Administered by Gavage to CD Sprague-Dawley Rats. Reproductive and Developmental Toxicology Laboratory, Research Triangle Institute, NC. Laboratory report No: 65C-5724-01/02. GLP/Unpublished.

Tyl, R.W., Marr, M.C. and Myers, C.B. 1994. Developmental toxicity Evaluation of Chlorophacinone Administered by Gavage to New Zealand White Rabbits. Reproductive and Developmental Toxicology Laboratory, Research Triangle Institute, NC. Laboratory report No:65C-5724-03/04. GLP/Unpublished.

Weill, N. 1990. Test to evaluate the Induction of Genic Mutations in CHO Cells (HGPRT Locus) Chlorophacinone. Hazleton France, France. Laboratory report No: 006301. GLP/Unpublished.

Anon. Title: Principles of medical supervision of employees exposed to Difethialone, Bromadiolone and Chlorophacinone-based rodenticides.

Anon. Title: The treatment of anticoagulant rodenticide poisoning – Advice to physicians. Personal communication

Anon. Title: The treatment of anticoagulant rodenticide poisoning – Advice to veterinarians

ENVIRONMENT

Adam, D., 2003, 14C-chlorophacinone: Hydrolysis at three different pH values. RCC Ltd., laboratory report no. 849153, 10 December 2003 (unpublished)

Curl, M.G., 2004, The estimation of photochemical oxidative degradation of chlorophacinone. TSGE, laboratory report no. 12 1 12.POD, 21 January 2004 (unpublished)

Diehl, M., (2004), 14C-chlorophacinone: Aqueous Photolysis Under Laboratory Conditions. RCC Ltd, Laboratory Report No. 948165, 04 March 2004 (unpublished)

Machado, M.W. (1992a). Chlorophacinone - Acute toxicity to rainbow trout (*Oncorhynchus mykiss*) under flow-through conditions. Springborn Laboratories, Inc., laboratory report number 91 12 4025, 18 May 1992 (unpublished)

Machado, M.W. (1992b). Chlorophacinone - Acute toxicity to bluegill sunfish (*Lepomis macrochirus*) under flow-through conditions. Springborn Laboratories, Inc., laboratory report number 92 1 4079, 18 May 1992 (unpublished)

Peither, A. (2003). Toxicity of chlorophacinone to *Scenedesmus subspicatus* in a 72 hour algal growth inhibition test, RCC Ltd., laboratory report number 844814, 14 January 2003 (unpublished)

Peither, A., 2003, Ready biodegradability of chlorophacinone in a manometric respirometry test, RCC Ltd., laboratory report no. 844816, 14 January 2003 (unpublished)

Peither, A. (2003). Toxicity of chlorophacinone to activated sludge in a respiration inhibition test. RCC Ltd., laboratory report number 844817, 14 January 2003 (unpublished)

Putt, A.E. (1992). Chlorophacinone - Acute toxicity to daphnids (*Daphnia magna*) under flow-through conditions. Springborn Laboratories, Inc., laboratory report number 91 11 3998, 6 May 1992 (unpublished)

Spare, W., 1992, Soil photolysis, Agrisearch Inc., laboratory report no. 1418, 10 August 1992 (unpublished)

Spare, W., 1993, Adsorption / desorption of chlorophacinone in four soil types, Agrisearch Inc., laboratory report no. 1416, 26 January 1993 (unpublished)

Spare, W., 1994, Aerobic soil metabolism of chlorophacinone, Agrisearch Inc., laboratory report no. 1419, 18 January 1994 (unpublished).